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The genetic and molecular basis of mammalian cardiac development 
was studied in two model systems: German shepherd dogs (GSDs) afflicted 
with inherited juvenile ventricular arrhythmias and the dark-like (dal) mutant 
mouse, which I identify as a new model for studying myocardial development. 
GSDs with inherited juvenile ventricular arrhythmias and sudden 
cardiac death are an established model for studying cardiac ventricular 
arrhythmias. The inheritance of this disease in GSDs is consistent with a major 
gene that allows a dog to be affected and modifiers that influence severity. 
Genome-wide linkage analysis was performed to identify the loci responsible, 
but no strong evidence of linkage was detected. As altered calcium 
homeostasis has been observed in the hearts of these dogs, I examined 
cardiac expression levels of genes implicated in calcium handling. A significant 
inverse correlation was observed between the levels of ATP2A2 RNA and its 
protein product, SERCA2, and severity of ventricular arrhythmias, but no 
mutations were found in the ATP2A2 coding sequence. SERCA2 is a calcium 
pump located on the sarcoplasmic reticulum (SR) that sequesters cytosolic 
calcium back to the SR. My work indicates that SERCA2 is a molecular 
determinant of severity of ventricular arrhythmias in GSDs and suggests that 
at least one of the causative genes acts upstream of ATP2A2 transcription.
Mice homozygous for the dal mutation are small and have darkly 
pigmented fur. A spectrum of previously unrecognized developmental cardiac 
abnormalities was observed in dal mutant embryos, including a thickening of 
ventricular walls, atrial and ventricular septal defects, and enlarged 
endocardial cushions. No significant differences were detected in the 
proliferation status of mutant and control embryonic ventricles, but dal mutant 
embryonic cardiomyocytes were significantly larger than those of controls. 
This indicated that the thickened ventricles of dal mutant embryos result from 
developmental cardiac hypertrophy. Functional consequences associated with 
hypertrophy included early afterdepolarizations (EADs) and significant 
irregularities in the Ca2+ transient interval. Positional cloning identified a four 
base pair deletion in the peptidase D (Pepd) gene and morpholino knockdown 
of Pepd expression in zebrafish confirmed that Pepd loss of function disrupts 
normal myocardial development, pigmentation and body size. Pepd encodes 
prolidase, an enzyme involved in collagen metabolism. I hypothesized that 
loss of prolidase function in dal mutant embryos causes cardiac hypertrophy 
by disrupting the extracellular matrix and integrin signaling. Accordingly, I 
demonstrated reduced expression of integrin transducers and disrupted 
cytoskeletal organization in dal mutant embryonic hearts. My work provides a 
novel understanding of the genetic and molecular basis of developmental 
cardiac hypertrophy and has implications for the mechanisms that control the 
normal postnatal transition from proliferative to hypertrophic cardiomyocyte 
growth. These studies provide important insights into the genetic and 
molecular mechanisms underlying developmental cardiac disorders and will 
provide useful insights into understanding the pathogenesis of similar human 
heart diseases.  
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CHAPTER 1 
LITERATURE REVIEW 
Normal cardiac development  
Cardiac morphogenesis is a complex process. The earliest cardiac progenitors 
arise from lateral plate mesoderm under the control of proteins secreted from 
the adjacent endoderm. These proteins include fibroblast growth factors 
(FGFs), bone morphogenetic proteins (BMPs), and Wnt proteins (Srivastava, 
2006). Nkx2.5 is a transcription factor necessary for specification of the 
cardiac lineage. It directly activates transcription of the Mef2 (myocyte 
enhancer factor 2) gene, which is involved in myocyte differentiation. Cardiac 
progenitors are arranged in bilateral fields on either side of the prechordal 
plate and rostral notochord. These fields contain both myocardial and 
endocardial precursor cells (Tam et al., 1997). The bilateral fields of the 
cardiogenic mesoderm merge at their anterior margins to form the cardiac 
crescent (Brown et al., 2005). A second type of heart field is located medially 
in the splanchnic mesoderm, adjacent to the cardiac crescent. The cells from 
this anterior heart-forming field are fated to generate anterior heart structures 
of the outflow tracts (Kelly and Buckingham, 2002). The earliest steps of 
assembly of the heart tube, initiated by the fusion of the bilateral heart 
primordial along the midline, are controlled by the GATA transcription factor 
(Bisaha and Bader, 1991). The beating tubular heart is composed of an 
external myocardial and an internal endocardial layer. It also possesses a 
polarity along the anteroposterior axis, where the prospective tissues of the 
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outflow tract, right ventricle, left ventricle, and atria are arranged in an anterior 
to posterior order along the heart tube (Christoffels et al., 2000).  
The tubular heart undergoes a process called rightward looping, which is 
essential for proper orientation of the right and left ventricles and for alignment 
of the heart chambers with the vasculature. The direction of cardiac looping is 
determined by the asymmetrical expression of Sonic hedgehog (Shh) and 
Nodal, a member of the transforming growth factor-β (TGF-β) family, and 
affects the position of the internal organs. Left-right signals are translated to 
the organ primordia by the transcription factor Pitx2, which is expressed along 
the left side of developing embryo (Okada et al., 2005). Further septal division 
of the chambers and formation of cardiac valves are essential steps leading to 
the formation of an integrated 4-chambered heart. Regulatory genes encoding 
transcription factors such as Gata4, Gata5, Gata6, Tbx1(also known as 
Brachyury), Tbx5 and Nkx- 2.5 are involved in specification, trabeculation, and 
differentiation of the heart (Anversa and Nadal-Ginard, 2002; Zaffran and 
Frasch, 2002). In mammalian hearts, the transcription factors HAND1 and 
HAND2 are expressed predominantly in the primitive left and right ventricular 
segments, respectively (Srivastava et al., 1995). Interestingly, only the right 
ventricular marker HAND2 is expressed in zebrafish heart, which consists of 
one ventricle and one atrium.  
Prior to trabeculation (development of the finger-like projections comprised of 
ventricular cardiomyocytes), the heart tube consists of an outer myocardial 
layer that is separated from an inner endocardial cell layer by an intervening 
matrix called cardiac jelly. Signaling from the endocardium to the ventricular 
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myocardium initiates the conversion of the myocardium into a thickened 
ventricular myocardial chamber wall capable of contraction. This process 
includes the proliferation, differentiation, and migration of cells out of the 
myocardial layer into the lumen of the ventricle to form trabeculae at the outer 
curvature of the looped heart tube (Icardo and Fernandez-Teran, 1987).  
The trabecular myocardium is largely responsible for the maintenance of blood 
flow during development. Several signal transduction pathways are involved in 
formation of myocardial trabeculation and myocardial growth. These include 
the retinoic acid (RA), neuregulin/ErBb, serotonin, vascular endothelial growth 
factor (VEGF), and bone morphogenic protein-10 (BMP-10) pathways. 
Neuregulin growth factor, secreted from the endocardium, and its myocardial 
receptors, ErbB2 and ErbB4, are required for development of trabeculae (Lee 
et al., 1995). Transgenic mice over-expressing the cardiac-specific growth 
factor BMP-10 developed hyper-trabeculated hearts (Chen et al., 2006). 
Further analysis of these mutants showed that BMP-10 plays a critical role in 
formation of the trabeculated myocardium by regulating both the proliferation 
of cardiomyocytes and postnatal hypertrophic growth to provide appropriate 
numbers of cells to the compact ventricular wall critical for normal heart 
function (Chen et al., 2006).  
Blood flow through a chambered heart requires synchronized pumping 
between different heart chambers. Proper formation of the cardiac valve is 
critical to ensure that blood flows in one direction and to prevent backflow in 
the opposite direction. The precursors of valves, called cardiac cushions, form 
between atria and ventricles within the atrioventricular canal. In the AV canal, 
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cushion formation begins when the cardiac jelly expands and swells into the 
cushion primordial that becomes cellularized via the influx of mesenchymal 
cells (Eisenberg and Markwald, 1995). These cells come from the endocardial 
cell layer from which they have delaminated after undergoing an epithelial-to-
mesenchymal transformation (EMT) process. The signals that direct the 
endocardium to form AV endocardial cushions include BMP-2, Wnt, Notch, 
TGF-β, vascular endothelial growth factor (VEGF), neurofibromin, and 
extracellular matrix (ECM) produced by endocardial cells (Ramsdell et al., 
1998). The successful integration of these various signaling pathways is 
crucial to heart development since abnormalities of the myocardium and 
valves comprise the majority of congenital heart defects.  
The development of the sympathetic nervous system is a coordinated process 
for the sympathetic lineage and expression of catecholaminergic and neuronal 
traits. Neural crest cell-derived precursor cells migrate ventrally, aggregate 
adjacent to the dorsal aorta and ultimately differentiate into catecholaminergic 
neurons (Anderson, 1993). Transcription factors whose expression coincide 
with these differentiation events are MASH1, eHAND, dHAND, Phox2a, and 
Gata-2 (Groves et al., 1995). Cell number is refined during a period of cell 
death when neurotrophic factors, such as nerve growth factor (NGF) and 
neurotrophin (NT-3), determine the number of neuronal precursors and 
neurons that survive (Groves et al., 1995). Sympathetic neurons transport 
NGF from target tissues, and application of NGF to nerve terminals maintains 
sympathetic neurons. During development, increasing NGF levels rescues 
sympathetic neurons that normally die, whereas decreasing NGF causes 
destruction of the sympathetic nervous systems (Albers et al., 1994). NT-3 
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acts later in development to maintain dividing sympathetic precursors that are 
not responsive to NGF, and NT-3 increases the survival of precursors isolated 
from embryonic sympathetic ganglia (Verdi et al., 1996).  
Embryonic cardiac growth is mainly accomplished by hyperplasia of 
myocardial cells, and further hypertrophic growth of the heart after birth makes 
the heart 30- to 40-fold larger during postnatal maturation (Figure 1.1) (Oparil 
et al., 1984). The molecular and genetic mechanisms of this transition process 
from hyperplasia to hypertrophy remain largely unknown. A role for cardiac 
fibroblasts was elucidated in embryonic myocardial development (Ieda et al., 
2009). This study suggested that cardiac fibroblasts are not merely a 
supportive structure, but rather provide a microenvironment, via the secretion 
of growth factors and extracellular matrix proteins, that allows cardiomyocytes 
and cardiac fibroblasts to communicate. This group found that embryonic 
cardiac fibroblasts regulate the proliferation of cardiomyocytes through the 
secretion of extracellular matrix proteins (collagen, fibronectin), and that β1 
integrin signaling plays a critical role in this process.  
Congenital cardiac defects arise from abnormal heart development during 
embryogenesis. Even subtle perturbations in cardiogenesis can cause cardiac 
malformations with devastating consequences. While some of the genetic and 
molecular mechanisms have been identified, much remains to be learned.  
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Figure 1.1. Normal transition of cardiomyocyte growth from hyperplasia 
to hypertrophy. Myocardial growth during prenatal developmental stages is 
mainly accomplished by hyperplasia, which increases the number of 
cardiomyocytes. Shortly after birth (postnatal day 3 in mice), cardiac 
hyperplasia is terminated and cardiomyocytes undergo hypertrophic changes, 
which make the heart 30- to 40-fold larger during postnatal maturation.  
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Abnormal cardiac development I: Ventricular arrhythmias and sudden 
cardiac death 
The heart spontaneously and repetitively generates electrical impulses. These 
electrical impulses organize the sequence of muscle contraction under the 
control of the autonomic (sympathetic and parasympathetic) nervous system 
during each heartbeat, which is vital to optimize the cardiac stroke volume. 
Cardiac electrical excitation originates in the sinoatrial node and activates the 
atria. The impulse then traverses the bundle of His, bundle branches and the 
Purkinje system to activate the ventricular myocardium, which generates 
strong forces to pump blood into the circulatory system. A laminar electrical 
propagation through this tightly orchestrated electrical system is fundamental 
to all cardiac function. The resting intracellular transmembrane voltage is 
negative and the magnitude of the negativity varies for different cells. The 
magnitudes for the sinoatrial nodal cell and Purkinje fiber are -60mV and -
90mV, respectively. Activation of a cell is associated with a sudden and rapid 
reversal of the intracellular negativity during phase 0 (a sudden influx of 
sodium reverses the intracellular negativity) and phase 1 (the positive 
overshoot). Phase 2 is fairly stable and any changes during this phase are due 
to slow calcium channel fluxes, which play a significant role in the generation 
of the action potential of sinoatrial (SA) and atrioventricular (AV) nodal cells. 
The transmembrane negativity is restored during phase 3 with efflux of 
potassium. Phase 4 follows to restore normal ionic concentration and to finish 
a cycle of electrical and contraction coupling (E-C coupling). Phase 0 
represents cardiac electrical depolarization, while repolarization encompasses 
phases 1 through 4 (Figure 1.2). Deregulation of this electrical system impairs  
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Figure 1.2. Cardiac action potential. Ion channels play important roles in 
generating the cardiac action potential. Sodium influx into cardiomyocytes 
triggers phase 0 depolarization, followed by phase 1 through 4 repolarization 
periods via calcium and potassium currents.  
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normal electrical propagation in the heart and manifests as rhythm 
disturbances (cardiac arrhythmias), where the heart’s ability to pump enough 
blood to systemic circulation and maintain adequate coronary circulation is 
debilitated.  
Among the types of cardiac arrhythmias, polymorphic ventricular arrhythmias 
(torsades de pointes) often accompany more detrimental consequences, such 
as syncope (loss of consciousness) or sudden cardiac death, than 
supraventricular arrhythmias. Various genetic diseases can predispose to fatal 
inherited ventricular arrhythmias. Inherited ventricular arrhythmic disorders are 
divided into two subgroups: familial electrical disorders and arrhythmogenic 
cardiomyopathies (Roberts and Brugada, 2003). The primary electrical 
disorders, where organic heart disease is not detectable, include long QT 
syndrome, Brugada syndrome, idiopathic ventricular fibrillation, 
catecholaminergic polymorphic ventricular tachycardia (CPVT) and idiopathic 
right ventricular outflow tract tachycardia (RVO-VT). Arrhythmogenic 
cardiomyopathies, where a primary myocardial disease manifests with 
ventricular arrhythmias, include hypertrophic cardiomyopathy (HCM), dilated 
cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy 
(ARVC). These cardiomyopathies primarily result from mutations in genes that 
encode sarcomeric proteins, which generate the mechanical contraction of 
cardiomyocytes (HCM) (Marian and Roberts, 1995) cytoskeletal proteins, 
which coordinate and transmit the forces to the next cells (DCM) (Olson et al., 
1998), or ion channels, which regulate electrical activity in the heart (familial 
arrhythmias) (Roden et al., 1996). A failure to coordinate ion channels, ion 
currents, and structural proteins leads to perturbed transmission of electrical 
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and mechanical impulses across cardiomyocytes. This can degenerate into 
fatal ventricular arrhythmias and cause cardiac sudden death.  
Despite genetic and phenotypic heterogeneity in the etiology of inherited 
ventricular arrhythmias, the mechanism underlying arrhythmogenesis 
generally falls into one of three categories: i) increased automaticity; ii) 
electrical re-entry; or iii) triggered activities such as early afterdepolarizations 
(EADs) or delayed afterdepolarizations (DADs). Abnormal cardiac sympathetic 
innervation has been documented in long QT and Brugada syndromes 
(Vincent, 1998). Modulation of the autonomic tone is considered to be an 
important modifier in triggering polymorphic ventricular arrhythmias with ion 
channel defects. Cardiac electrical re-entrant waves can be generated by 
several predisposing substrates, such as cardiac scar formation, ischemia, 
inflammation, increased wall stress (hypertrophy) due to pressure or volume 
overload, or heterogeneous refractoriness across the myocardium. In 
particular, maintenance or sustainability of arrhythmias predominantly 
depends on this re-entrant mechanism. Early afterdepolarizations (EADs) are 
one form of triggered activity that can occur during phase 3 of the cardiac 
action potential. Delayed afterdepolarizations (DADs) are another form of 
triggered activity that can take place during phase 4. These 
afterdepolarizations from the myocardium or purkinje fibers during the early 
(EADs) or late (DADs) repolarization period can provide substrates to provoke 
new action potentials and degenerating torsades de pointes.  
There is a close relationship between intracellular calcium handling and 
triggered activities, as demonstrated by the example of digitalis toxicity. DADs 
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occur in conditions of intracellular calcium overload due to digitalis overdose 
by inhibiting the sodium-potassium ATPase pump (Clusin, 2003). DAD-
dependent ventricular arrhythmias are one of the common side effects in 
cardiac patients with digitalis administered. This indicates that disturbed 
calcium homeostasis plays a pivotal role in the genesis of triggered activities 
and resultant ventricular arrhythmias. In addition, spontaneous calcium 
release in cardiomyocytes or purkinje fibers can also lead to 
afterdepolarizations with sufficient amplitude to trigger an ectopic beat 
(Michael et al., 2009). Furthermore, patients with end-stage heart failure or 
cardiac hypertrophy often develop fatal ventricular arrhythmias where a 
considerable prolongation of calcium transients and a drastic decline in the 
activity of the sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA) 
pump are demonstrated (Berridge, 2006).  
Abnormal cardiac development II: Integrin signaling and hypertrophic 
remodeling 
Integrins comprise a large family of cell surface receptors that exist as 
heterodimers of α and β subunits. Vertebrates express 18 different integrin α-
subunits and 8 β-subunits, making integrins the most structurally and 
functionally diverse family of cell-adhesion molecules (Howe et al., 1998). 
Importantly, integrins (one of the predominant ECM receptors) function as 
mechanotransducers, converting mechanical forces to biochemical signals. 
The large extracellular domain of the integrin receptor complex binds various 
ECM proteins (collagen, laminin and fibronectin), while a short cytoplasmic 
domain interacts with the cytoskeleton within the cell, influencing myofibrillar 
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and cytoskeletal assembly in cardiomyocytes (Hilenski et al., 1991). The 
cytoplasmic domains of integrins also bind directly to several protein tyrosine 
kinases, including focal adhesion kinases (FAK), Src family kinases, paxillin, 
and integrin-linked kinase (ILK), which play essential roles in orchestrating 
multiple functions in cell growth, differentiation, migration, and organogenesis 
(Figure 1.3) (Curley et al., 1999). Thus, the binding of a specific ECM ligand 
(such as collagen) to an integrin receptor elicits the activation of intracellular 
signaling, cytoskeletal reorganization and changes in cell adhesion or 
migration (DeSimone et al., 1987).  
An altered balance of numerous different stimuli, such as mechanical forces, 
neurohormonal activation, growth factors, and cytokines can trigger a 
defective hypertrophic response and cardiac remodeling (Frey and Olson, 
2003). In cardiomyocytes, integrin-dependent pathways mediate hypertrophic 
responses to mechanical stimuli and are required for stimulation of 
hypertrophy in response to trophic agents such as phenylephrine or endothelin 
(Aikawa et al., 2002). Mechanical stress-induced increases in sarcomere 
length change the spatial arrangement of the actin filament network that link z-
discs (Bloom et al., 1996). Over-expression of β1-integrin in cardiomyocytes 
was found to increase atrial natriuretic peptide (ANP) levels (ANP is a marker 
of hypertrophic changes), which demonstrates that integrins influence the 
hypertrophic response in cardiomyocytes (Kuppuswamy et al., 1997). FAK is 
also implicated in cardiac development as conditional knockout of FAK in 
mouse cardiomyocytes resulted in cardiac defects and ventricular hypertrophy 
(Peng et al., 2008). 
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Figure 1.3. Integrin activation mediates downstream signaling cascades. 
Integrins are heterodimers consisting of noncovalently-associated alpha (a) 
and beta (b) subunits. They mediate adhesion of cells to the ECM and cell to 
cell interactions. Integrin receptors are considered to provide a cellular link 
between the ECM and the cytoskeleton. The downstream signals that follow 
integrin activation trigger modifications of signal-transducers, including FAK 
(focal adhesion kinase), Src and Paxillin, which leads to alterations in cell 
morphology, cell growth, or cell migration as well as the regulation of cell cycle 
progression.  
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Many genetic and molecular mechanisms in cardiac development and 
congenital heart diseases, however, still remain determined. Forward genetic 
approaches where a phenotypic characterization is followed by the 
identification of the mutated gene will determine genes and pathways that 
underlie developmental cardiac disorders. 
Approaches for mapping phenotypic trait loci 
Phenotypic trait loci vary from major gene mutations causing simple Mendelian 
trait differences to quantitative trait loci (QTLs) that underlie complex traits. 
Phenotypic traits can be either monogenic (under the control of a single gene 
locus) or multigenic (under the control of more than one locus). There are two 
major approaches for mapping phenotypic trait loci: the candidate gene 
approach and genome-wide linkage analysis. The candidate gene approach 
can be a powerful and effective method for gene discovery. The disadvantage 
of the candidate gene approach, however, is its reliance on existing 
knowledge about the biology of the phenotype since molecular details of most 
biological phenomena remain largely unknown. In comparison, genome-wide 
linkage analysis usually proceeds without presumptions regarding known 
functional features of the trait and identifies chromosomal regions responsible 
for the trait in pedigree- or population-based structures, which eventually 
provides a large number of candidate genes for mutation screening within the 
candidate interval.  
‘Linkage’ defines the situation where two loci are inherited together because  
15 
 
they are close to each other on a chromosome. Two linked loci tend to be co-
inherited because crossing-over is unlikely to occur between them in a given 
meiosis, because of their physical proximity. The closer two loci are to each 
other, the lower the probability of recombination between them. ‘Linkage 
analysis’ is a test for detecting co-segregation of a chromosomal region (i.e. a 
marker) with a trait of interest, which is determined by variation/ mutation in a 
specific gene or genes. The aims of linkage analysis are to narrow down the 
genomic region responsible for the phenotype, and ultimately to identify the 
causative mutation.  
Mapping loci using inbred mice which are homozygous at virtually every locus 
has a unique advantage since highly divergent inbred lines can be mated to 
produce mice segregating different alleles at the target locus and at DNA 
markers throughout the genome. Two types of crosses are generally used in 
mouse genetics: backcross (BC) and intercross (F2). In a backcross, F1 
hybrids produced from mating two different inbred strains are mated back to 
one of the parental strains. In an intercross, F1 hybrids are mated to each other 
to produce an F2 population. After genotyping outcross mice for selected DNA 
markers, genotype data can be analyzed to map the chromosomal region 
linked to the trait where genotypes at mutation (based on phenotypes) 
correlates with genotypes at markers. Animals with recombination events 
between each marker and the target locus can be identified to map the 
recombination breakpoints and define the smallest common haplotype block, 
which is indicative of candidate interval harboring the locus.  
Mendelian traits are comparatively easy to study, but account for a small 
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proportion of human and animal diseases, most of which are multigenic in 
nature, exhibiting quantitative variation. These include cardiovascular disease, 
seizure, obesity and cancer (Wright et al., 2003). Complex traits are analyzed 
by linkage analysis to detect linkage between genetic markers and the loci 
responsible for the phenotypic variation. The variance component method, in 
particular, has gained wide popularity and is a way to assess the amount of 
variation in a dependent variable that is associated with a random-effects 
variable (Visscher et al., 1999). This method can be used to analyze a large 
pedigree without knowing the mode of inheritance (Blangero et al., 2000) and 
allele sharing statistics are based on identity by descent (IBD) at the marker 
locus, where IBD analysis estimates the probability that two individuals share 
marker alleles that are inherited from a common ancestor within the pedigree 
(Almasy and Blangero, 1998). Since all linkage techniques are essentially 
designed to test for a statistical association between inheriting a specific 
parental allele at a genetic marker and the mutation that underlies a 
phenotypic trait, statistical power for detecting linkage is influenced by 
pedigree size and structure, sample size, marker informativeness, penetrance, 
distance of marker from the disease locus, genetic heterogeneity and the 
magnitude of the genetic effect. 
The dog genome is less diverged from the human than the mouse genome 
and has approximately the same number of genes as humans. Long linkage 
disequilibrium (LD) and haplotype blocks in most canine breeds allows for 
genome-wide association mapping studies with fewer markers and fewer 
individuals compared to human (Lindblad-Toh et al., 2005). In association 
mapping, two groups (affected and unaffected) are compared to identify 
17 
 
haplotype blocks that are frequently observed in the affected group but not in 
the unaffected group. Sequence information from several breeds of dogs has 
enabled the identification of more than 2 million single nucleotide 
polymorphisms (SNPs) in the canine genome that can be used for association 
mapping. It is estimated that a SNP occurs every 1000 bases in dogs 
(Lindblad-Toh et al., 2005). In contrast to microsatellite markers, which are 
less abundant and display multiple alleles, SNPs are the most common type of 
polymorphism in the genome and are biallelic. Canine SNP chips harboring 
about 27,000 SNPs that provide uniform genome coverage are now 
commercially available. Since many human diseases also affect dogs, 
mapping disease loci in dogs can identify genes and pathways relevant to 
human disease. 
Summary  
Congenital heart defects are the most common birth defects. Dissecting the 
genetic and signaling pathways important for heart development and function 
will not only help to better understand disease pathogenesis, but also have 
clinical applications such as early diagnostic testing and therapeutic 
interventions, which will eventually benefit animal health as well as human 
well-being. Animal models provide excellent opportunities to study the genetic 
and molecular basis of cardiovascular diseases. The following chapters will 
present the studies of developmental cardiac disorders in canine and murine 
models. 
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CHAPTER 2 
INHERITED VENTRICULAR ARRHYTHMIAS IN GERMAN SHEPHERD 
DOGS 
Introduction 
Cardiovascular disease is known as the most common cause of mortality and 
morbidity. In particular, sudden cardiac death is responsible for a substantial 
portion of total mortality in cardiac patients. A recent report estimated the 
annual incidence of sudden cardiac deaths to be in the range of 180,000 to 
250,000 in the United States (Chugh et al., 2008). The most important pre-
existing etiology of sudden cardiac death is malignant polymorphic ventricular 
arrhythmias, for which the pathophysiologic and genetic mechanisms remain 
to be elucidated.  
Ventricular arrhythmias can be acquired or inherited. Acquired ventricular 
arrhythmias are commonly associated with underlying diseases, including 
cardiomyopathies, coronary artery diseases, heart failure, hypertension, 
diabetes mellitus, and renal failure. Since primary inherited ventricular 
arrhythmias were first diagnosed in a human family with long QT syndrome in 
1957 (Jervell and Lange-Nielsen, 1957), extensive efforts have been made 
through basic research and clinical studies to dissect the genetic risk factors 
that cause inherited forms of ventricular arrhythmias to degenerate into 
sudden arrhythmic death. Currently, familial hereditary ventricular arrhythmias 
in human medicine include long QT syndrome, Brugada syndrome, short QT 
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syndrome, and polymorphic ventricular tachycardia. Underlying mutations 
have been identified in genes encoding sodium channels, potassium channels, 
gap junction proteins, and the ryanodine receptor. It has been noted, however, 
that disease penetrance is incomplete and the phenotypic spectrum varies (for 
example, some individuals die suddenly while family members carrying an 
identical mutation are asymptomatic). This indicates that familial hereditary 
ventricular arrhythmias in human are not simple autosomal traits (Cheng et al., 
2003). Further investigations need to be carried out to identify genetic 
modifiers that contribute to the wide spectrum of phenotypic expression of 
arrhythmias using animal models with spontaneous ventricular arrhythmias 
and sudden death. Murine cardiac physiology somewhat differs from human, 
however, with regard to heart size, heart rate, developmental aspects, ion 
channel compositions, and action potential characteristics, which makes a 
large animal model (i.e., dogs) more suitable for conducting complex 
physiological studies.   
A colony of German shepherd dogs (GSDs) with a genetic predisposition to 
spontaneous ventricular arrhythmias and sudden death has been established 
by Dr. N. Sydney Moïse at Cornell University (Moise et al., 1994). Quantitative 
phenotypic variation in the number and frequency of ventricular arrhythmias is 
evident in these dogs, ranging from very few ectopic beats to life-threatening 
cardiac rhythm disturbances. A window of vulnerability for the presence of 
ventricular arrhythmias and sudden cardiac death exists between 12 and 50 
weeks of age, with peak affectedness occurring between 20 and 28 weeks. 
Interestingly, affected dogs rarely continue to have this disease after 18 to 24 
months of age (Moise et al., 1997a). When it occurs, death is unexpected and 
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most frequent during rapid eye movement sleep or at rest after exercise. 
Although echocardiographic and post-mortem examinations revealed no 
functional or structural abnormalities in the hearts of affected GSDs, 
examination of cardiac innervation revealed sympathetic denervation in the left 
anterior apical regions of affected GSDs (Dae et al., 1997).  
Multiple subcellular abnormalities have been identified in the hearts of affected 
GSDs. Cardiac electrophysiological analysis revealed abnormal calcium 
oscillation, calcium overload, prominent early afterdepolarizations (EADs), as 
well as delayed afterdepolarizations (DADs) and decreased density of 
potassium channels (Sosunov et al., 1999; Steinberg et al., 2002). These 
abnormalities are considered to be responsible for the modification of cardiac 
repolarization in the region of sympathetic denervation, which could provide 
substrates for developing ventricular arrhythmias. Phenotypic similarities 
between GSDs with ventricular arrhythmias and humans with familial 
ventricular arrhythmias include sudden death during sleep or at rest after 
exercise, young age of onset of arrhythmias, a broad phenotypic spectrum, 
heterogeneous sympathetic innvervation, abnormal repolarizations (EADs and 
DADs), altered ion channel functions, and normal cardiac structure and 
hemodynamics. This makes the GSD particularly suitable for studies to 
understand the genetic and molecular mechanisms of arrhythmogenicity in 
human populations.  
Calcium cycling regulates excitation-contraction (E-C) coupling. Calcium entry 
through the L-type calcium channel stimulates calcium-induced calcium 
release from the sarcoplasmic reticulum calcium store via the ryanodine 
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receptor (RyR). During diastole, calcium is removed from the cytoplasm by 
resequestration back into the SR through sarcoplasmic-endoplasmic reticulum 
calcium ATPase (SERCA) and Na/Ca exchanger (NCX) located in the 
sarcolemma. Phospholamban inhibits the SERCA pump via phosphorylation, 
and calsequestrin stabilizes intra-SR calcium. Signaling between the RyR and 
SR luminal calcium is mediated by two small SR proteins, junctin and triadin. 
Prolonged action potential duration caused by Na+- or K+-channel dysfunction 
allows excessive calcium entry through L-type calcium channels and manifests 
EADs (Sicouri et al., 1997; Thomas et al., 2007). Excessive doses of digitalis 
produce calcium overload in the SR, which in turn induces spontaneous 
release of calcium (DADs) through RyRs (Sicouri and Antzelevitch, 1993). 
These findings suggest that abnormal calcium cycling can be a substrate to 
trigger afterdepolarizations (EADs and DADs). I therefore hypothesized that 
abnormal expression of the calcium handling genes described above may be 
responsible for abnormal calcium cycling seen as EADs and DADs in the GSD 
model of spontaneous ventricular arrhythmias.  
A previous study had suggested that arrhythmic phenotypes in GSDs do not 
follow simple dominant or recessive inheritance, but rather complex mode of 
inheritance (Cruickshank et al., 2009). Crosses between mildly affected dogs 
produced severely affected offspring, as well as unaffected dogs. Breeding 
severely affected dogs to severely affected dogs produced unaffected dogs, 
as well as severely affected ones. Mating unaffected GSDs with affected 
GSDs produced offspring with a full range of affectedness (from unaffected to 
severely affected). These observations are consistent with inherited ventricular 
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arrhythmias in GSDs being caused by a major gene for susceptibility and a 
small number of modifier genes that determine severity.  
The goals of this study were to: 1) map the underlying genetic mutations that 
contribute to ventricular arrhythmias in GSDs and 2) determine whether the 
expression of major cardiac calcium handling genes (ATP2A2, NCX1, RYR2, 
CASQ2, PLB, LTCC, and TRDN) differ between unaffected and affected 
GSDs in the least innervated region of the myocardium. While the mapping 
studies did not identify strong regions of linkage, the results of the second 
study provide evidence that SERCA2 levels are a key determinant of the 
severity of inherited ventricular arrhythmias in GSDs. 
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Materials and Methods 
Dogs and tissues 
All dogs were housed and fed in controlled conditions in AAALAC-approved 
facilities at Cornell University. All experimental procedures using animals in 
this study were performed according to protocols approved by the Cornell 
University Institutional Animal Care and Use Committee. A closed colony of 
purebred GSDs with ventricular arrhythmias has been established and has 
produced more than 400 dogs over 7 generations. One hundred and forty 
GSDs and their parents whose blood samples were available in the archive 
were selected from three sire families (Max, Harvey and Dr. Pepper). As the 
incidence of developing severe arrhythmias increased in GSD colony over 7 
generations of breeding, a pedigree with higher genetic and phenotypic 
heterogeneity was required for linkage analysis. Thus, a backcross pedigree 
was generated to introduce genetic and phenotypic diversity (Table 2.1). A 
severely affected female GSD from purebred GSDs was out-crossed to a male 
Greyhound dog to produce F1 dogs. Although the arrhythmic phenotypic 
information of this Greyhound dog was not available, this dog was considered 
to be an unaffected, normal dog because Greyhound dogs are not generally 
predisposed to any types of inherited cardiac disorders. Two unaffected F1 
hybrids were crossed back to female and male GSDs with severe ventricular 
arrhythmias.  
A total of 13 GSDs, 9 BC and 1 beagle samples were randomly selected from 
the archive of liquid nitrogen snap-frozen cardiac tissues for gene expression  
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Table 2.1. Phenotype data for 38 backcross dogs and their parents 
dog ID sire dam sex breed #Single PVCs #couplets #triplets #runs 
Pollux * * M GH * * * * 
S292 S254 S099 F GSD 26521 22 3 2 
S306 S297 S270 F GSD 5000 1434 729 17 
S313 S297 S154 M GSD 5000 4384 108 12 
S419 Pollux S292 F F1 4 0 0 0 
S420 Pollux S292 F F1 12 0 0 0 
S421 Pollux S292 M F1 352 0 0 0 
S422 Pollux S292 M F1 0 0 0 0 
S423 Pollux S292 M F1 28 0 0 0 
S482 S422 S292 F BC 29079 428 153 4 
S483 S422 S292 F BC 112 2 0 0 
S484 S422 S292 F BC 2405 4 0 0 
S485 S422 S292 M BC 0 0 0 0 
S487 S422 S306 M BC 0 0 0 0 
S488 S422 S306 M BC 21 0 0 0 
S489 S422 S306 F BC 8 4 3 0 
S506 S422 S292 F BC 1 0 0 0 
S507 S422 S292 F BC 0 0 0 0 
S508 S422 S292 F BC 378 0 0 0 
S509 S422 S292 M BC 6 0 0 0 
S510 S422 S292 M BC 2 0 0 0 
S511 S422 S292 M BC 204 0 3 16 
S512 S313 S419 M BC 15081 77 0 2 
S513 S313 S419 M BC 4 0 0 0 
S514 S313 S419 M BC 1168 84 6 0 
S515 S313 S419 M BC 20388 4346 714 89 
S516 S313 S419 F BC 2331 2 0 0 
S517 S313 S419 F BC 306 0 0 0 
S518 S313 S419 F BC 2697 179 29 0 
S519 S313 S419 F BC 2 0 0 0 
S520 S313 S419 F BC 103655 1592 158 22 
S521 S422 S306 F BC 2 0 0 0 
S522 S422 S306 F BC 29580 19957 1094 114 
S523 S422 S306 F BC 0 0 0 0 
S524 S422 S306 F BC 7478 203 3 0 
S525 S422 S306 F BC 88 0 0 0 
S526 S422 S306 F BC 0 0 0 0 
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Table 2.1. Phenotype data for 38 backcross dogs and their parents 
(Continued) 
dog ID sire dam sex breed #Single PVCs #couplets #triplets #runs 
S562 S422 S292 F BC 0 0 3 2 
S563 S422 S292 F BC 3125 825 6 0 
S564 S422 S292 F BC 1634 22 0 1 
S565 S422 S292 M BC 28272 0 0 0 
S566 S422 S292 M BC 1 0 0 0 
S567 S422 S292 M BC 0 0 0 0 
S574 S422 S306 F BC 1 2 0 0 
S575 S422 S306 F BC 0 0 0 0 
S576 S422 S306 M BC 870 0 0 0 
S577 S422 S306 M BC 2343 0 0 0 
 
studies (Table 2.2). All dogs were 5 months of age when tissue was collected. 
Affectedness score for each dog was determined based on the classification in 
Tables 2.3 and 2.4. The beagle sample was used as a calibrator for qRT-PCR. 
This dog was euthanized for reasons unrelated to this study. It had no history 
or clinical signs of heart disease or conditions likely to cause abnormal cardiac 
electrophysiology.  
Phenotypic quantification of ventricular arrhythmias 
The incidence and severity of arrhythmias peak at 5~7 months of age and 
decline over the period of puberty. Surviving dogs grow out of the arrhythmias 
by 12~18 months of age (Moise et al., 1997b). Phenotype data are collected 
from 24 hour Holter recordings performed at about 5 months of age, to 
diagnose and quantify ventricular arrhythmias. In cases where multiple 
recordings were available for a given dog, its worst Holter recording  
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Table 2.2. Holter recordings and affectedness category for 22 dogs used 
for quantitative RT-PCR 
ID # Breed Single Couplet Triplet Run Score Category 
S 509 BC 44 0 0 0 1 mild 
S 519 BC 25 0 6 0 5 mild 
S 450 GSD 33621 285 0 0 4 mild 
S 413 GSD 100 0 0 0 1 mild 
S 466 GSD 147 0 3 0 1 mild 
S 511 BC 204 0 3 16 13 moderate 
S 476 GSD 1264 44 1822 0 11 moderate 
S 469 GSD 796 284 60 9 13 moderate 
S 412 GSD 36635 6096 216 5 16 severe 
S 517 BC 5150 11 20 6 14 severe 
S 477 GSD 6860 1290 297 13 22 severe 
S 439 GSD 46534 24924 8967 400 26 severe 
S 449 GSD 24594 288 32 49 20 severe 
S 440 GSD 13145 48184 387 286 22 severe 
S 457 GSD 64904 18134 702 166 26 severe 
S 453 GSD 20026 248 17 17 20 severe 
S 522 BC 29580 19957 15588 8441 16 severe 
S 523 BC 2 0 0 0 0 UA 
S 521 BC 2 0 0 0 0 UA 
S 507 BC 2 0 0 0 0 UA 
S 506 BC 3 0 0 0 0 UA 
S 451 GSD 3 0 0 0 0 UA 
27 
 
 
* : a cumulative value from four ordinal trait scores for each dog           
 
 
(i.e., giving the most severe phenotype) was selected as the phenotype data. 
The phenotypic spectrum of ventricular arrhythmias was categorized into 4 
different traits: single premature ventricular complexes (PVCs), couplets (two 
consecutive PVCs), triplets (three PVCs in a row), and runs of ventricular  
tachycardia (more than 3 consecutive PVCs). The number of ventricular 
ectopic beats for each trait (single PVCs, couplets, triplets, and runs of VT) 
was counted after manual review of every single beat by experienced 
technicians. For quantitative real time PCR analysis, each individual’s 
phenotype was classified as an ordinal trait (mild, moderate, severe, 
unaffected) after calculating the affectedness score based on the classification 
proposed in Tables 2.3 and 2.4. Except for the presence of fatal ventricular 
arrhythmias, no hemodynamic or structural abnormalities were documented in 
Table 2.3. Cutoff values for scoring affectedness 
Category Score* 
Unaffected (UA) 0 
Mildly affected 1~5 
Moderately affected 6~13 
Severely affected (SA) ≥14 
Table 2.4. Affectedness categorization of ventricular arrhythmias 
 Range Score Range Score Range Score
Singles ≤5 0 5< X ≤5000 1 >5000 2 
Couplets ≤5 0 5< X ≤500 2 >500 4 
Triplets ≤5 0 5< X ≤500 4 >500 8 
Runs <1 0 1≤ X ≤10 6 >10 12 
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the pedigree of GSDs. Pedigree analysis also revealed no sex effect on 
affectedness (Cruickshank et al., 2009).  
Multiplex PCR and fragment analysis 
Genomic DNA from 140 German shepherd dogs (GSDs), 38 BC dogs and 
their parents and grandparents were isolated from whole blood leukocytes 
using a standard ammonium acetate/ethanol protocol. A genome wide screen 
was performed using 320 microsatellite markers that comprise the Minimal 
Screening Set 2 (MSS2), for which the average marker distance is 9 Mb and 
average heterozygosity is 0.73 (Clark et al., 2004). Primer sequences are 
available at (http://research.nhgri.nih.gov/dog_genome). Primers were 
synthesized by Sigma Aldrich. Forward primers were labeled with one of four 
fluorescent dyes: 6-FAM (blue), NED (yellow), PET (red), or VIC (green). 
These markers can be combined into 96 multiplexed panels with 3 to 6 
markers in each panel, grouped together based on compatible annealing 
temperatures, dye colors and allele sizes (Clark et al., 2004). All multiplex sets 
were amplified with an identical step-down thermal cycling program: 5 min at 
95°C followed by 4 cycles of 30s at 95°C, 20s at 58°C, and 20s at 72°C and 
an additional 30 cycles of 20s at 95°C, 20s at 56°C, and 20s at 72°C, with a 
final extension of 5 min at 72°C. A single master mix, excluding primers, was 
used for all multiplex and individual reactions. Amplified PCR products were 
mixed with an internal size standard (GeneScan 500 LIZ, Applied Biosystems) 
and formamide in a MicroAmp optical 384-well reaction plate, denatured at 
95°C for 3 minutes and chilled on ice for 5 minutes. Plates were then 
submitted to the BioResource Center at Cornell University for analysis on an 
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ABI 3730 automatic sequencer (Applied Biosystems). Assignment of the allelic 
peaks was confirmed by a manual inspection of each eletrophoretogram with 
GeneMapper 3.5 software (Applied Biosystems). 
Linkage Analysis  
Parametric and non-parametric linkage analyses were conducted to increase 
the chance of detecting genomic region(s) responsible for ventricular 
arrhythmias in GSDs. It was hoped that common or overlapping regions of 
linkage would be identified by both approaches.   
I: Parametric SUPERLINK linkage analysis 
Genotypes were checked for Mendelian inheritance errors using the Pedigree 
Check program in Pedtool (http://bioinfo.cs.technion.ac.il/superlink-
online/makeped/pedcheck). The Parametric SUPERLINK program 
(http://bioinfo.cs.technion.ac.il/superlink-online) was used to calculate 
multipoint logarithm of the odds (LOD) scores that tested for linkage between 
genotype at microsatellite markers and arrhythmic phenotypes in the BC 
pedigree. The GSD pedigree was too large to be compatible with this program. 
Since the specific mode of inheritance of the ventricular arrhythmias in the BC 
pedigree is not certain, linkage analysis was run (separately) for both 
dominant and recessive modes of inheritance. As the penetrance of inherited 
ventricular arrhythmias is also undetermined, it was set at 0.5. Marker allele 
frequencies were assumed to be equal. As parametric linkage analysis via 
SUPERLINK required designating disease status (either affected or 
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unaffected), the cutoff values for affectedness were set at >100 single PVCs, 
>8 couplets, >6 triplets, or >1 run of VT (N. Sydney Moϊse, personal 
communication). Each individual dog’s worst Holter record was used to 
determine its affectedness based on these cutoff values.  
II: Non-parametric SOLAR linkage analysis 
A pedigree-based multipoint variance component approach was used to test 
for linkage between genotype at marker loci and phenotype using the actual 
number of ventricular ectopic beats from each dog’s worst Holter recording to 
map genomic region(s) responsible for arrhythmias in GSDs with the software 
program Sequential Oligogenic Linkage Analysis Routines (SOLAR) (Almasy 
and Blangero, 1998). SOLAR employs a maximum likelihood method. As the 
use of the variance component approach in Solar program required an 
estimate of the identity-by-descent (IBD) matrix in the pedigree, the program 
LOKI (Lee and Thomas, 2000), which employs a Markov chain Monte Carlo 
stochastic procedure, was used to compute the IBD allele sharing matrix from 
genotype data for each marker locus. Marker maps for 38 autosomes were 
generously provided by Dr. Rory Todhunter. Since pedigree information did 
not show a sex effect on affectedness (Cruickshank et al., 2009), sex 
chromosomes were excluded from linkage analysis.  
Expression analysis of calcium handling genes  
Total myocardial RNA from liquid nitrogen snap-frozen cardiac tissue taken 
from the anterior apical left ventricular wall was isolated using Qiagen RNeasy 
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Fibrous Tissue Mini kit. Total RNA was eluted into 50 µl of RNase-free water. 
RNA integrity and quality was determined using the Agilent 2100 Bioanalyzer 
(Agilent technologies, Santa Clara, CA) and the concentration measured using 
a Nanodrop ND-100 spectrophotometer (Thermo Scientific, Wilmington, DE). 
RNA samples were diluted to 22 ng/µl and 220 ng used in a 20 µl reverse 
transcription (RT) reaction along with 10X RT buffer, 25X dNTP mix (100mM), 
10X RT random primers, 1 µl MultiscribeTM reverse transciptase, and 
nuclease-free water using the ABI High Capacity cDNA Reverse Transcription 
Kit. The 2X RT master mix reactions were incubated at 25°C for 10 min, 37°C 
for 120 min, then 5 sec at 85°C. Transcribed cDNA samples were diluted 7-
fold in nuclease-free water and stored at -80°C. The same cDNA samples 
were used for all subsequent PCR assays.  
The Primer3 program (http://frodo.wi.mit.edu) was used to design primers to 
amplify a portion of 7 target genes involved in Ca2+ homeostasis: ATP2A2, 
NCX1, RYR2, CASQ2, PLB, LTCC, and TRDN. Primers were designed to 
amplify a 100-150 bp region of cDNA flanking at least one large intron, so that 
products amplified from cDNA could be distinguished from any amplified 
genomic DNA that might contaminate the RNA samples. Primers were also 
designed to amplify 101 bp of the Glucose-6-Phophate Isomerse (GPI) 
transcript, which was used as an endogenous control for normalization of 
cDNA input. The sequences of the PCR primers are listed in Table 2.5. 
Quantitative Real Time PCR (qRT-PCR) was performed using the ABI 7500 
Real time PCR System and the Power SYBR green PCR master mix kit  
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1: Sarcoplasmic-Endoplasmic Calcium ATPase 
2: L-type Calcium Channel 
3: Calsequestrin 
4: Sodium-Calcium Exchanger  
5: Phospholamban 
6: Ryanodine Receptor 
7: Triadin 
8: Glucose-6-Phophate Isomerse 
 
(Applied Biosystems, Foster City, CA). Each reaction was mixed with 5µl of 2X 
SYBR Green Master Mix, 1 µl of 10mM primer mix (forward and reverse), 1 µl 
of cDNA template, and RNase-free water up to 10 µl. Reactions were loaded 
into a MicroAmp 96-well plate and sealed with a MicroAmp optical cap. Each 
sample was assayed in duplicate. A negative control (nuclease-free water 
used as template in place of cDNA) was run with each set of experiments. 
Table 2.5. Primer sequences used to amplify cDNA of major calcium 
handling genes. 
Genes Primer Sequence 
ATPA21 F-CCTTGAGGACTCTGCCAACT R-CAGAGGAGGCCACTTCAATC 
LTCC2 F-CAGCATCGTCGAATGGAAAT R-GTTCCAGGTTGGAATTGGTG 
CASQ3 F-AAGTCGCGCAGAAACAGTTC R-GCTTCTTTCTTGGCATCCAC 
NCX14 F-AATGTGTCGTAGCCCTGAGC R-GAGGAGTGCAAACCCCACTA 
PLB5 F-AACACCGATAAGACTTCATACAACTC R-CCAAATGTGAGCTCAACCAC 
RYR26 F-GCAACCATCCACAAAGAACA R-GCAGATGGAGAGGTCTGGAG 
TRDN7 F-TCCAACCACCATGACTGAGA R-AGCACTTTTCCAGGGGATTT 
GPI8 F-AGAACCTTGTGACCGACACC R-CGATCCTCCGTGAAGTTGAT 
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Reactions were incubated at 50°C for 2 min to activate uracil N’-glycosilase 
and then for 10 min at 95°C to inactivate the uracil N’-glycosilase and activate 
the polymerase, followed by 40 cycles of 15s at 95°C, 30s at 60°C, and 30s at 
72°C. PCR reactions were then subjected to the 7500 Real Time PCR System 
heat dissociation protocol. As SYBR green dye can bind to all double-stranded 
DNA molecules including primer-dimers, melting curve analysis was 
conducted to distinguish any contaminating genomic DNA from the desired 
products. The fold change in target gene levels relative to the GPI 
endogenous control was determined by the 2-∆∆Ct method, where ∆∆Ct = 
(CtTarget – CtGPI)GSD  –  (CtTarget – CtGPI)beagle. The Ct (threshold cycle) value was 
calculated based on the time (measured in PCR cycle number) at which SYBR 
green fluorescent emission increased beyond a threshold bar and became 
visible to the system (Livak and Schmittgen, 2001). 
A greater copy number of input mRNA target therefore results in a lower Ct 
value as a result of requiring fewer PCR cycles for SYBR green fluorescent 
intensity to reach the threshold. The calibrator sample (beagle) was included 
on every assay plate. The relative quantification (RQ) value for each sample 
was calculated as the ratio between the amount of target molecule and a 
reference molecule (GPI). The normalized RQ value was used for statistical 
analysis of differential gene expression using Spearman’s rank correlation test 
and Student’s t-test in the GraphPad Prism 5 statistical program. Spearman’s 
rank correlation test was used to examine the relationship between two 
variables, RQ value and affectedness score. Student’s t-test compared the 
mean of RQ values between unaffected and affected (mild, moderate or 
severe) GSDs. Since the same samples were used to estimate the expression 
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level of 7 genes, the correlation and mean difference were considered 
significant at p-value of 0.007 (=0.05/ 7 genes), determined by a Bonferroni 
correction for multiple testing.  
Immunoblotting analysis of SERCA expression 
Frozen heart tissue from the left ventricular anterio-apical (LVAA) region of 3 
unaffected dogs (s507, s521, s523) and 3 severely affected dogs (s453, s457, 
s522) was homogenized with a Polytron homogenizer in RIPA buffer (50mM 
Tris HCl pH7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% SDS) 
supplemented with Complete protease inhibitor cocktail (Roche, Germany). 
Homogenates were centrifuged at 12000 rpm for 5 minutes at 4°C and the 
supernatant collected and stored at -80°C. Protein concentrations were 
determined by BCA protein assay (Pierce, Rockford, IL). Equal amounts of 
protein lysates (20 μg of total protein) were mixed with 2X SDS buffer (125 
mM Tris-HCl, 10% glycerol, 10% SDS, 130 mM DTT), incubated at 70°C for 5 
minutes and separated on 4% stacking, 8% SDS polyacrylamide gels. 
Proteins were transferred to Immobilon P membrane (Millipore, Bedford, MA) 
at 0.5 mA for 3 hours. The membrane was blocked with 5% dry milk in Tris-
Tween Buffered Saline (TTBS) for 12 hours at 4°C and incubated for 3 hours 
at 4°C with an antibody against SERCA2 (cat#:ab2861, Abcam, Cambridge, 
MA) diluted 1:2000 in TTBS. The blot was washed, incubated with horseradish 
peroxidase (HRP)-conjugated anti-mouse secondary antibody (cat#:554002, 
BD Transduction Laboratories, San Jose, CA) in TTBS for 50 min at room 
temperature followed by three 15 min washes in TTBS. Antibody signal was 
detected by chemiluminescence (ECL Western Blotting Detection Reagent, 
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Amersham, UK) and visualized using the Versadoc Imaging system (Bio-Rad, 
Hercules, CA). The membrane was re-blotted with a HRP-conjugated antibody 
against GAPDH (cat#: ab9482, Abcam) to check for equal protein loading. 
Densitometry was performed using Quantity One Software (Bio-Rad). 
Differences between mean values was considered statistically significant at 
p<0.05. 
ATP2A2 sequence analysis 
Total RNA was extracted from 2 unaffected dogs (GS7, BC13) and 2 severely 
affected dogs (GS2, GS23). RT was performed using Superscript III First-
Strand cDNA kit with an oligo-dT primer (Invitrogen). Eight pairs of overlapping 
primers spanning the full length ATP2A2 cDNA were designed to generate 
~700-1000 bp PCR products (Table 2.6). PCR was performed using i-Proof 
high fidelity DNA polymerase (Bio-Rad) with the following amplification 
conditions: denaturation at 94°C for 30s, annealing 64°C for 30s, and 
extension at 72°C for 90s for 40 cycles of amplification. PCR products were 
purified using the QIAquick Gel Extraction Kit (Qiagen) and PCR products 
sequenced from both forward and reverse directions on an ABI 3730 
sequencer (Applied Biosystem) at the Sequencing Core Facility in the 
BioResource Center at Cornell University. SeqMan software (DNAStar Inc.) 
was used to align and compare sequence data for affected dogs against 
unaffected dogs and the boxer consensus sequence available at the Ensembl 
genome browser. 
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Results 
Susceptibility to ventricular arrhythmias follows a complex mode of 
inheritance 
Previous studies had suggested a complex mode of inheritance for ventricular 
arrhythmias in the closed colony of GSDs (Cruickshank et al., 2009). Crosses 
between mildly affected dogs produced severely affected offspring as well as 
unaffected dogs. Breeding severely affected dogs to severely affected dogs 
produced unaffected dogs as well as severely affected ones.  
Table 2.6. Primers used to sequence cDNA of ATP2A2 gene. 
Primer name Primer Sequence 
ATP2A2_F1 GCAGGAGGAGGAGGAGGA 
ATP2A2_R1 CGGATCTTGCCAATTTCTGT 
ATP2A2_F2 GGGTGTATGGCAGGAGAGAA 
ATP2A2_R2 GGGAGCAGCTATCACCTTCA 
ATP2A2_F3 CAGCTTTCCAAAGTCATCTCC 
ATP2A2_R3 CCTGGGGTCATAGGGACTT 
ATP2A2_F4 GGATTACAATGAGGCGAAGG 
ATP2A2_R4 AGGAGCATCATTCACACCATC 
ATP2A2_F5 AATCTGACTTTCGTTGGATGC 
ATP2A2_R5 GTGGCTCAGCTGGTAGAAGG 
ATP2A2_F6 AAATGTGGGGGAGGTTGTCT 
ATP2A2_R6 CACACAATGAGTTGGGGACTT 
ATP2A2_F7 CCCCCTGGGAGAACATCT 
ATP2A2_R7 GCACCAACATCTGTCTACTGCT 
ATP2A2_F8 GAGGTTCCAAAACCTTATCTAAGAA 
ATP2A2_R8 TTTACCTGAAACCATGTCTGTG 
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Mating unaffected GSDs with affected GSDs produced offspring with a full 
range of affectedness (from unaffected to severely affected GSDs). Genetic 
analysis also demonstrated a relatively high heritability for affectedness and 
severity of ventricular arrhythmias in GSDs.  
In order to produce a BC population for linkage mapping, a severely affected 
female GSD (ID: s292) was outcrossed to a presumed unaffected male 
Greyhound dog (ID: Pollux) to produce 5 F1 hybrids. Two F1 were unaffected 
while 3 were mildly affected (Table 2.1). The fact that 3 F1’s were affected, 
albeit mildly, suggests that a dominant major locus determines susceptibility to 
ventricular arrhythmias. The unaffected F1 hybrids were mated back to 3 
severely affected GSDs, including the dam (s292) of F1 hybrids. A total of 38 
BC dogs were produced (Table 2.1). The cross between an unaffected F1 and 
his mother (s292) produced 7 unaffected and 9 affected BC dogs. This is 
consistent with a dominant major gene for which the dam (s292) was 
heterozygous. Twenty three (61%) dogs in the BC population were affected: 7 
dogs were severely, 2 moderately and 13 mildly. Affected BC dogs showed a 
wide spectrum of affectedness (from mild to severe). This implies the 
presence of a major gene with modifiers that influence severity. The settings 
for affectedness categorization, however, are somewhat arbitrary (Tables 2.3 
and 2.4) and might under-represent severity for some dogs. 
Mapping susceptibility loci for ventricular arrhythmias in GSDs 
As pedigree analysis demonstrated an inherited genetic component for 
susceptibility of GSDs to ventricular arrhythmias, a genome-wide linkage 
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analysis was undertaken to map the loci responsible. Genotypes for 140 GSD, 
38 BC dogs and their parents were determined for the MSS2 panel of 
microsatellite markers. Two separate linkage programs, SUPERLINK and 
SOLAR, were used for each pedigree to increase the chance of detecting 
genomic region(s) linked to the disease and the results were compared to try 
to find overlapping genetic region(s) common to the two pedigrees. In this way, 
it was hoped that false positive and negative results would be reduced or 
eliminated. Both programs run a pedigree-based analysis and all results are 
based on relationships within the pedigree. The former is a model-based 
parametric linkage analysis program which requires a parameter defining the 
mode of inheritance, whereas the latter is a non-parametric model-free method 
and thus better suited to a pedigree in which a complex trait is segregating. 
Given the uncertainty regarding the mode of inheritance of ventricular 
arrhythmias in GSDs, a non-parametric multipoint linkage analysis was first 
used to test for linkage between marker loci and cardiac phenotype. Non-
parametric approaches are often more powerful when some assumptions 
(such as mode of inheritance) that are important to the analysis are 
questionable or may not be met. Since SOLAR uses an IBD matrix calculated 
by LOKI (a Markov chain Monte Carlo procedure), the BC and GSD 
populations were analyzed separately. As shown in Table 2.7 and 2.8, none of 
the markers showed strong evidence of linkage to ventricular arrhythmias in 
either pedigree. The highest LOD score observed was ~2.3 for runs at 43 cM 
on CFA11 in the 140 GSDs (Table 2.8), but LOD scores for all traits across 
CFA11 in the BC pedigree were 0 (Table 2.8). 
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As the non-parametric approach was not successful in identifying significant 
linkage between affectedness for arrhythmias and any chromosomal region, a 
parametric linkage analysis was also performed using the SUPERLINK 
program. The large size of the GSDs pedigree was not compatible for use with 
this program, so SUPERLINK analysis was only run using data for the 38 BC 
dogs. The results for dominant and recessive modes of inheritance were 
equivalent. The highest LOD scores detected for each ordinal trait and their 
map positions are summarized in Table 2.9. It was interesting to note that all 
the suggestive or strong LOD scores (>2.2) were for triplets (Table 2.9). 
Potential loci for triplets mapped to the same positions on CFA 2, 3, 9, 15, 25 
and 32 as more weakly suggestive LOD scores (values of 0.94-1.85) for 
couplets. Positive LOD scores (~0.7) were also observed for couplets, triplets 
and runs at the same position on CFA 23.  
Overall, the linkage studies did not identify any consistent region(s) of linkage 
for the 4 ordinal traits. It is possible that one or more of the putative modifiers 
that influence severity map to one of the regions described above since a 
modifier might be expected to only influence a subset of the more severe traits. 
Several of the regions with suggestive LOD scores are likely to represent false 
positive results, however, since the number of potential loci identified exceeds 
the likely number of modifier loci. 
ATP2A2 is differentially expressed in affected GSDs  
As the genome-wide scan described above did not provide strong support for 
linkage between any chromosomal region(s) and susceptibility to ventricular 
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Table 2.7. Linkage analysis for BC pedigree by SOLAR program 
single couplet triplet run 
LOD cM LOD cM LOD cM LOD cM 
cfa1 0.198 47 1.025 1 1.729 31 (FH3413) 0.233 63 
cfa2 0.581 66 0.005 31 0.046 50 0.000 0 
cfa3 0.048 23 0.211 53 0.000 0 0.000 0 
cfa4 0.000 0 0.015 63 0.023 62 0.327 31 
cfa5 0.003 68 0.029 52 0.000 0 0.000 0 
cfa6 0.707 35 0.151 76 0.000 0 0.000 0 
cfa7 0.110 0 0.000 0 0.000 0 0.000 0 
cfa8 0.000 0 0.623 73 0.000 0 0.000 0 
cfa9 0.033 68 0.043 40 0.000 0 0.000 0 
cfa10 0.233 72 0.549 63 0.940 72 0.040 52 
cfa11 0.000 0 0.000 0 0.000 0 0.000 0 
cfa12 0.146 62 0.468 46 0.000 0 0.000 0 
cfa13 0.017 53 0.000 0 0.023 60 0.000 0 
cfa14 0.059 55 0.026 47 0.000 0 0.000 0 
cfa15 0.061 44 0.000 0 0.000 0 0.000 0 
cfa16 0.407 40 0.886 30 0.242 7 0.000 0 
cfa17 0.007 75 0.000 0 0.000 0 0.000 0 
cfa18 0.076 40 0.019 40 0.000 0 0.000 0 
cfa19 0.081 51 0.000 0 0.000 0 0.000 0 
cfa20 0.000 0 0.113 23 0.112 23 0.000 0 
cfa21 0.054 20 0.523 13 0.545 10 0.000 0 
cfa22 0.000 0 0.000 0 0.000 0 0.000 0 
cfa23 0.000 0 0.000 0 0.000 0 0.000 0 
cfa24 0.000 0 0.000 0 0.027 7 0.000 0 
cfa25 0.000 0 1.274 13 0.335 21 0.000 0 
cfa26 0.000 0 0.192 22 0.000 0 0.000 0 
cfa27 0.000 0 0.050 20 0.000 0 0.000 0 
cfa28 1.164 44 0.379 44 1.587 44 (REN146G17) 1.216 31 
cfa29 0.978 19 0.581 15 0.146 2 0.000 0 
cfa30 0.012 34 0.008 14 0.080 25 0.000 0 
cfa31 0.000 0 0.000 0 0.000 0 0.000 0 
cfa32 0.002 22 0.000 0 0.000 0 0.000 0 
cfa33 0.516 16 0.035 23 0.000 0 0.000 0 
cfa34 0.784 0 0.356 0 0.049 0 0.000 0 
cfa35 0.000 0 1.322 11 0.000 0 0.000 0 
cfa36 0.052 14 0.088 1 0.000 0 0.000 0 
cfa37 0.000 0 0.000 0 0.000 0 0.622 34 
cfa38 0.000 0 0.007 36 0.211 33 0.169 33 
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Table 2.8. Linkage analysis for GSD pedigree by SOLAR program 
single couplet triplet run 
LOD cM LOD cM LOD cM LOD cM 
cfa1 1.5669 35 (FH3413) 0.6287 34 0.3565 34 0.2823 34 
cfa2 0 0 0 0 0 0 0 0 
cfa3 0.057 84 0 0 0 0 0.006 14 
cfa4 0.4519 9 0.1941 85 0.6763 88 0.1017 87 
cfa5 0.6469 89 0.4513 89 0.2904 102 0 0 
cfa6 0.0731 11 0 0 0.0193 0 0.0366 0 
cfa7 0.7603 85 0.6249 99 0.4524 86 0 0 
cfa8 0.6725 55 0.0684 46 0 0 0.0929 33 
cfa9 0.0081 41 0 0 0 0 0.0366 24 
cfa10 0.0008 51 0 0 0.2528 48 0.4116 48 
cfa11 0.8206 32 1.7446 30 (REN242K04) 1.554 31 2.2987 
43 (FH2004 
,FH2319 ) 
cfa12 0.4872 52 0.247 51 0 0 0 0 
cfa13 0 0 0 0 0 0 0 0 
cfa14 0.7708 13 0 0 0.4157 57 0.0501 47 
cfa15 0.1473 51 0 0 0 0 0 0 
cfa16 0.6944 0 0 0 0.0123 60 1.6389 2 (REN214L11)
cfa17 0 0 0 0 0 0 0.3 75 
cfa18 0 0 0 0 0 0 0 0 
cfa19 0 0 0.104 21 0.1625 19 0.3688 34 
cfa20 0.3118 11 0.1437 49 0 0 0.4352 32 
cfa21 0 0 0 0 0 0 0 0 
cfa22 0 0 0.5775 60 0.2236 43 0 0 
cfa23 0.2661 53 0.254 50 0.2021 12 0.6298 0 
cfa24 0.1478 25 0 0 0 0 0 0 
cfa25 0 0 0.7 43 0.4426 43 0.18 44 
cfa26 0.5427 38 1.1247 38 (FH2130) 0 0 0 0 
cfa27 0 0 0 0 0 0 0 0 
cfa28 0 0 0 0 0 0 0 0 
cfa29 0.3216 3 0.1372 7 0 0 0 0 
cfa30 0 0 0 0 0 0 0 0 
cfa31 0 0 0 0 0 0 0.3896 42 
cfa32 0.8189 33 0 0 0 0 0 0 
cfa33 0.3154 0 0.3699 0 0.4538 0 0.1142 0 
cfa34 0 0 0 0 0 0 0 0 
cfa35 0 0 0 0 0 0 0 0 
cfa36 0 0 0 0 0 0 0 0 
cfa37 0.0331 17 0 0 0.1308 4 0.3146 0 
cfa38 0.0012 33 0 0 0.0019 44 0 0 
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Table 2.9. Linkage analysis for BC pedigree by SUPERLINK program 
  single couplet triplet run 
  LOD cM LOD cM LOD cM LOD cM 
cfa1 0 0 1.33 97.73 (FH2309) 1.13 57.62 0.53 57.62 
cfa2 0 0 1.11 89.05 (C02.342) 2.29 
89.05  
(C02.342) 0 0 
cfa3 0 0 1.31 3.76 (FH3396) 1.95 3.76 0 0 
cfa4 0 0 0.40 56.79 0.40 56.79 0 0 
cfa5 0 0 0 0 0 0 0 0 
cfa6 0 0 0 0 0 0 0 0 
cfa7 0 0 0 0 0 0 0 0 
cfa8 0 0 0 0 0 0 1.12 18.74 (REN204K13) 
cfa9 1.52 49.93 (FH3835) 1.27 76.06 2.97 
76.06  
(FH2885) 0 0 
cfa10 0 0 0 0 0 0 0 0 
cfa11 0 0 0 0 0 0 0 0 
cfa12 0 0 0 0 0 0 0 0 
cfa13 0 0 0 0 0 0 0 0 
cfa14 0 0 0 0 0 0 0 0 
cfa15 0 0 0.94 38.88 2.44 38.8  (FH3813) 0 0 
cfa16 0 0 0 0 0 0 0 0 
cfa17 0 0 0 0 0 0 0 0 
cfa18 0.99 62.70 0 0 0.55 8.04 0 0 
cfa19 0 0 0 0  0 0 0 0 
cfa20 0 0 1.33 31.28 (REN100J13) 3.37 
20.84  
(FH2951) 0 0 
cfa21 0 0 0 0  0 0 0 0 
cfa22 0 0 0 0  0 0 0 0 
cfa23 0 0 0.69 44.56 0.71 44.56 0.71 44.56 
cfa24 0 0 0 0  0 0 0 0 
cfa25 0 0 1.67 37.7 2.31 37.7  (FH2141) 0 0 
cfa26 0 0 0 0  0 0 0 0 
cfa27 0 0 0 0  0 0 0 0 
cfa28 0 0 0 0 0 0 0 0 
cfa29 0 0 0 0 0.91 7.4 0 0 
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arrhythmias in GSDs, an alternative candidate gene approach was used to 
identify the underlying genes. In human medicine, a significant correlation has 
been established between abnormal calcium signaling and heart failure. 
Importantly, altered calcium homeostasis has also been implicated in the 
genesis of ventricular arrhythmias (Goldhaber et al., 2005; Wan et al., 2005). 
As described in Introduction section, I hypothesized that differences in the 
expression of major calcium handling genes might underlie the abnormal 
calcium oscillation observed in the hearts of affected GSDs. Any genes 
differentially expressed in affected GSDs would be examined as candidate 
susceptibility loci.  
Quantitative RT-PCR for ATP2A2, NCX1, RYR2, CASQ2, PLB, LTCC, and 
TRDN was performed on heart RNA isolated from colony GSDs and BC dogs 
that ranged in disease severity from unaffected to severely affected for 
ventricular arrhythmias. The RQ value was calculated for each gene. Student’s 
Table 2.9. Linkage analysis for BC pedigree by SUPERLINK program 
(Continued) 
  single couplet triplet run 
  LOD cM LOD cM LOD cM LOD cM 
cfa30 0 0 0 0  0 0 1.14 32.07 (FH2290) 
cfa31 0 0 1.00 13.87  0 0 0 0 
cfa32 0 0 1.85 45.86 2.51 45.86  (AHT127) 0 0 
cfa33 0 0 0.52 0  0 0 0.82 20.42 
cfa34 0 0 0 0  0 0 0 0 
cfa35 0 0 0.42 34.72 0.90 6.22 0.43 34.72 
cfa36 0 0 0 0  0 0 0 0 
cfa37 0 0 0 0  0 0 0 0 
cfa38 0 0 0 0  0 0 0 0 
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t-test was first performed to identify gene(s) that were differentially expressed 
between unaffected and affected dogs. Among the 7 candidate genes, only 
ATP2A2 showed a statistically significant difference between mean RQ values 
(Table 2.10 and Figure 2.1A). ATP2A2 encodes the SR/ER calcium ATPase 
pump (SERCA) that plays an essential role in calcium homeostasis by 
sequestering cytosolic calcium back into SR. Additional statistical analysis 
using Spearman’s rank correlation coefficient tested whether there was a 
correlation between the RQ value and disease severity, which was estimated 
using an “affectedness” scoring system (Tables 2.3 and 2.4) that placed each 
dog into one of 4 groups (unaffected, mildly affected, moderately affected, and 
severely affected). Higher affectedness scores reflected more severe 
phenotypes. ATP2A2 expression showed a significant (inverse) correlation 
with disease severity (p<0.05; Table 2.10): in other words, the lower ATP2A2 
expression, the more severely affected a dog was (Figure 2.1B and Table 
2.10).   
In order to test whether reduced ATP2A2 expression in affected GSDs 
resulted in reduced SERCA2 protein levels, protein lysates from the hearts of 
3 of the unaffected and 3 of the severely affected dogs that were used for 
quantitative RT-PCR were subjected to immunoblotting using an antibody 
against SERCA2a (the cardiac isoform). Consistent with the altered RNA 
expression of ATP2A2, SERCA2a levels were reduced by ~40% in the hearts 
of severely affected dogs relative to unaffected dogs (Figure 2.2).  
The reduced expression of ATP2A2 in affected GSDs identified this gene as a 
candidate locus for susceptibility to ventricular arrhythmias. It should be noted 
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that ATP2A2 maps to 13.725 cM (11.167 Mb) on CFA 26, which was not 
identified as a region of linkage in the BC or GSD pedigrees (although positive 
LOD scores of 0.5 and 1.1 were observed at ~38 cM for singles and couplets, 
respectively, in SOLAR analysis of GSDs). The ATP2A2 coding region was 
amplified by RT-PCR from heart RNA of 2 severely affected and 2 unaffected 
GSDs. The product sequences were compared to each other and against the 
boxer sequence in the Ensembl database. Some single nucleotide 
polymorphisms were identified between the affected GSD and boxer sequence 
and also between affected and unaffected GSD. Protein sequence, however, 
was not predicted to be altered. No other sequence changes were identified.   
 
* Significant p<0.007 
 
 
  
Table 2.10. Cardiac expression of ATP2A2 was significantly reduced and 
correlated with affectedness in GSDs with ventricular arrhythmias. 
 Spearman’s rank correlation test Student’s t-test 
Genes p-value coefficient (r) p-value 
ATP2A2 0.003 (*) -0.7624 0.006 (*) 
CASQ2 0.315 -0.1612 0.334 
LTCC 0.637 -0.0991 0.455 
NCX1 0.194 -0.3073 0.249 
PLB 0.246 -0.2973 0.585 
RYR2 0.12 -0.3655 0.257 
TRDN 0.28 -0.2343 0.328 
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Figure 2.1. ATP2A2 was differentially expressed in the hearts of affected 
and unaffected dogs. (A) A significant difference was detected in the mean 
level of ATP2A2 expression between unaffected and affected dogs (* 
Student’s t-test, p=0.0063). (B) Relative quantification (RQ) value for the 
mRNA expression level of ATP2A2 was calculated for dogs with inherited 
ventricular arrhythmias. The RQ value of ATP2A2 is plotted against severity of 
the trait. Spearman’s rank correlation test revealed a significant inverse 
correlation between the expression level of ATP2A2 and disease severity, with 
a p-value of 0.003 and correlation coefficient of -0.7624.  
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Figure 2.2. SERCA2a expression was significantly lower in affected 
GSDs than in unaffected GSDs. (A) Western blot analysis showed that 
severely affected GSDs had lower levels of SERCA2a (100 kDa band) than 
unaffected GSDs. (B) Intensity of SERCA2a signal was normalized against 
GAPDH. The mean relative intensity of SERCA2a in the hearts of unaffected 
GSDs was almost twice as high as that in severely affected GSD hearts (* 
Student’s t-test p-value: 0.017).  
49 
 
Discussion 
While the phenotype of the GSD model of ventricular arrhythmias is fairly well 
understood, the future value of this model in contributing to the understanding 
of the molecular basis of human arrhythmogenic disease requires that the 
causative mutations be identified. This chapter describes my efforts to do so.  
Linkage analysis 
The cardiac phenotype in GSDs can be measured as a quantitative and 
continuous trait, represented by the number of PVCs and whether they occur 
as singles, couplets, triplets or runs. Pedigree analysis indicated that there is a 
strong genetic component to susceptibility to ventricular arrhythmias in these 
animals, best fitting a mode of inheritance where a major locus determines 
disease susceptibility and modifiers modulate the severity of disease. A 
genome-wide linkage analysis was performed to identify chromosomal 
region(s) linked to the GSD arrhythmogenic phenotype.  
I used both parametric linkage analysis (SUPERLINK) and non-parametric 
variance component linkage analysis (SOLAR) with multipoint IBD estimation 
by Markov chain Monte Carlo sampling method. SOLAR failed to identify any 
regions of significant linkage for any of the traits (single PVCs, couplets, 
triplets or runs), while SUPERLINK identified 1 significant and 5 suggestive 
regions of linkage, but only for triplets in the BC population. Triplets (three 
premature ventricular complexes in a row) are a more advanced type of 
ventricular ectopic beats than singles or couplets, which might indicate that at 
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least one of the loci with significant or suggestive LOD scores represents a 
modifier that influences disease severity in the BC population. It should be 
noted, however, that none of these regions were detected in the SOLAR 
analysis with GSDs or BC dogs, and parametric linkage analysis (SUPERLINK) 
is not ideal for the pedigree with complex mode of inheritance. Further studies 
are needed to test whether these regions contain modifying genes that 
provoke triplets by performing linkage analysis with additional microsatellite 
markers and/or SNPs in these and/or nearby the regions.  
There are several prerequisites to performing successful linkage analysis for a 
complex trait. Statistical power is influenced by pedigree size and structure, 
sample size, distance of marker from the disease locus and the magnitude of 
the genetic effect. The phenotype data must be reliable, well-defined and 
quantitative. A pedigree should be designed to maximize the informativeness 
of genetic variation within the population. The density and polymorphic content 
of DNA markers and accuracy of genotype data is also important. Each of 
GSD and BC pedigree had pros and cons regarding power. Sample size was 
higher in the closed colony of GSDs (140) than BC population (38), but genetic 
heterogeneity was much higher in the BC population. Failure to detect loci 
might reflect any combination of phenotyping errors, low marker density, 
genotyping errors, low penetrance, epistasis, and/or limited statistical power 
due to small sample size, especially in the BC population. 
GSDs with ventricular arrhythmias have no phenotypic abnormalities other 
than potentially fatal ventricular arrhythmias, which can only be reliably 
detected by Holter monitoring. An ambulatory 24 hour Holter recording has 
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been widely used to quantify and identify complex ventricular arrhythmias 
predictive of sudden cardiac death. The exact, quantitative phenotype data 
from Holter monitoring, however, can vary spontaneously from day-to-day 
(Spier and Meurs, 2004). The arrhythmias only occur in young animals: if an 
affected dog survives to 1-2 years of age, its arrhythmias disappear (Moise et 
al., 1997b). This makes accurate phenotyping one of the biggest challenges 
facing genetic mapping studies of this trait in GSDs. An important question is 
whether total number of PVCs is an appropriate way to define the 
arrhythmogenic phenotype for linkage analyses. For dogs whose Holter 
recordings were performed multiple times, their affectedness phenotype (total 
number of PVCs) was consistent with respect to a dog being categorized as 
unaffected or severely affected. For GSDs categorized as mildly or moderately 
affected, however, the number of PVCs was not as consistent. This implies 
that using total number of PVCs is not the best representation of phenotype for 
dogs in these intermediate categories. Also, limited statistical power in linkage 
analysis can be associated with pedigree structure and sample size. The 
pedigree of 140 GSDs may not have had a useful degree of heterozygosity at 
the marker loci. Traditional genetic crosses (for example, in mice) use inbred 
strains, whereas these GSDs are not inbred lines. A backcross pedigree was 
generated in order to introduce more genetic variation, but the relatively small 
sample size (38) limits the statistical power, increasing the probability of type II 
(false negative) errors.  
Microsatellite allele segregation analysis provides a useful tool in linkage 
analysis. I used 320 microsatellite markers for which the average marker 
spacing was 9 Mb and average heterozygosity was 0.73. The question 
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remains, however, as to whether this provided sufficient coverage of the 
canine genome and whether marker polymorphism was high enough in the 
GSD and BC pedigrees. A total of 73 of the 320 markers (23%) were not 
informative (only one or two alleles segregating in the pedigree). Moreover, 
microsatellites have their own intrinsic issues, as microsatellite “slippage” can 
occur during PCR amplification, and the length of microsatellite markers can 
change over time. Epistasis between susceptible loci and low heritability are 
other potential reasons for failure to detect linkage, although genetic analysis 
of ventricular arrhythmias in GSDs demonstrated a relatively high heritability of 
affectedness and severity of ventricular arrhythmias (Cruickshank et al., 2009).  
A different approach, called association mapping, appears to be a more 
suitable for mapping complex traits, and is becoming one of the main tools for 
fine-mapping and identifying loci (Andersson, 2008). In this method, two 
groups (affected and unaffected animals) are compared to identify haplotype 
blocks that are frequently observed in the affected group but not in the 
unaffected group. A haplotype block is a series of alleles on a chromosome 
that are inherited together. Sequence information from several breeds of dogs 
has enabled the identification of more than 2 million single nucleotide 
polymorphisms (SNPs) in the canine genome that can be used for association 
mapping. It is estimated that a SNP occurs every 1000 bases in dogs 
(Lindblad-Toh et al., 2005). In contrast to microsatellite markers, which are 
less abundant and display multiple alleles, SNPs are the most common type of 
polymorphism in the genome and are biallelic. Canine SNP chips harboring 
about 27,000 SNPs that provide uniform genome coverage are now 
commercially available. Therefore, an alternative approach that could be used 
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in the future is to perform a genome-wide association mapping study using 
SNP chips to identify haplotype blocks associated with ventricular arrhythmias 
in GSDs. Given ambiguities in defining correct affectedness for mildly or 
moderately affected dogs, I would recommend SNP genotyping only with 
definitively unaffected and severely affected dogs in the GSD pedigree. This 
would eliminate issues related to incorrect phenotyping and genotyping errors, 
and significantly increase marker density and genome coverage, which allows 
for fine-mapping in the initial genome-wide screen. The BC pedigree could be 
used for further fine mapping, as these animals carry recombination 
breakpoints that could help refine the position of the underlying mutation(s).   
In the meantime, a candidate gene approach may prove useful in identifying 
the genetic and molecular basis of ventricular arrhythmias in GSDs. Previously 
reported information (Sosunov et al., 1999) that GSDs manifested 
afterdepolarizations associated with calcium cycling led me investigate the 
expression of calcium handling genes. 
Differential ATP2A2 (SERCA2a) expression is implicated in aberrant 
calcium handling and severity to ventricular arrhythmias in GSDs         
Intracellular calcium dynamics have been extensively explored in models of 
inherited arrhythmias and heart failure (Clusin, 2003). For example, mutations 
in RYR2 have been identified in inherited catecholaminergic polymorphic 
ventricular arrhythmias (Katz et al., 2009). Extra diastolic calcium waves such 
as EADs and DADs are known to cause familial ventricular arrhythmias (Sato 
et al., 1993). Increased diastolic calcium leakage from the SR contributes both 
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to a decrease in SR calcium content and an increased susceptibility to 
ventricular arrhythmias in heart failure. However, the expression of calcium 
handling genes and their relationship to arrhythmogenicity has not been 
examined in models of familial ventricular arrhythmias. The Cornell GSD 
colony provides a unique opportunity to study calcium remodeling at the 
genetic and molecular level in familial ventricular arrhythmias.  
Arrhythmias in GSDs are similar to those in human disease, where diastolic 
calcium waves are proposed to be the cause of triggering fatal arrhythmias 
(Sicouri and Antzelevitch, 1993; Sicouri et al., 1997; Thomas et al., 2007). 
During the diastolic phase, 90% of cytosoilc calcium is pumped back to the SR 
through SERCA, whereas only 10% is extruded out of the cell via NCX (Marks, 
2000). SERCA pump function is thus positioned to be a critical determinant of 
intracellular calcium homeostasis. There are three different SERCA genes: 
SERCA1, SERCA2 and SERCA3, among which SERCA2a is the cardiac 
isoform. The roles of SERCA2a in the genesis of abnormal calcium handling 
and cardiac dysfunction have been studied. Seth et al. demonstrated that 
gene silencing of Atp2a2 by siRNA resulted in abnormal calcium signaling, 
including increased NCX expression and activity as a compensatory response, 
increased cytosolic calcium and depletion of internal calcium store (Seth et al., 
2004). This suggested that loss of SERCA2a function can trigger a cascade of 
abnormal calcium dynamics and calcium-related arrhythmias. Reduced 
expression of SERCA2a is a common finding in humans with heart failure and 
also accelerates the onset of heart failure (Lehnart et al., 1998; Schultz Jel et 
al., 2004).  
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Here, I report that among 7 candidate calcium handling genes, a significant 
correlation was observed only between ATP2A2 transcript level and severity of 
ventricular arrhythmias: severely affected GSDs had the lowest ATP2A2 
expression levels, unaffected GSD had the highest, and mildly and moderately 
affected dogs had intermediate levels. Interestingly, however, the expression 
of NCX or RYR2 did not show a significant difference between the unaffected 
and affected. This might suggest that ATP2A2 is the direct target of upstream 
genetic mutation in GSDs and ATP2A2 is a critical determinant of severity. 
These findings not only identify GSDs as an exceptional animal model to study 
calcium-related ventricular arrhythmias, but also reveal a unique signature of 
this particular disease.  
Mice deficient for the Sp1 transcription factor displayed ventricular arrhythmias 
and sudden death (Nguyen-Tran et al., 2000). Sp1, Sp3 and GATA4 are 
known to regulate ATP2A2 expression (Brady et al., 2003; Takizawa et al., 
2003). Since it failed to identify any strong region(s) of linkage on chromosome 
26 where ATP2A2 gene is located at 11.167 Mb (13.725 cM), it might be 
worthwhile to sequence the genes that encode these transcription factors as 
additional candidates for susceptibility to ventricular arrhythmias in GSDs. In 
fact, complex traits result from non-coding regulatory variants more often than 
from coding sequence variants (Mackay, 2001). While complete loss-of-
function of these genes would be expected to cause systemic and/or structural 
disorders, which are not observed in the GSDs, it is possible that a 
hypomorphic mutation could have a more specific effect on ATP2A2 
expression. Since significant portions of cardiac ventricles in GSDs lack 
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sympathetic innervation, sequence analysis for genes involved in sympathetic 
nerve development in the hearts should also be considered.  
A process called calcium-induced calcium release (CICR) triggers a robust 
calcium release into the cytosol to elevate intracellular calcium levels during 
systole. Intracellular calcium handling relies heavily on SR calcium content, as 
the SR is a major intracellular calcium reservoir. Finding reduced expression 
of ATP2A2 gene products in GSDs with ventricular arrhythmias, both at the 
RNA and protein level, suggests a partial loss of SERCA2a pump function. 
When SERCA2a function is disrupted, calcium ions which are supposed to be 
re-sequestered into the SR lumen during diastole would be expected to stay in 
cytosolic compartments far longer. SR calcium would become depleted over 
time and intracellular calcium concentration would rise. The NCX would then 
be hyper-activated in order to compensate for calcium overload inside the cells. 
Measuring the fluxes of the NCX and estimating SR calcium content would 
therefore be helpful in elucidating more detailed calcium dynamics at the 
cellular level in GSDs with ventricular arrhythmias.  
Cardiac relaxation during diastole requires the removal of cytosolic calcium 
back to the SR via SERCA2a, as well as out of the cell through the NCX. 
Previous studies, however, showed no evidence of systolic or diastolic 
dysfunction in GSD colony dogs (Moise et al., 1997b). Further investigations 
into the physiological consequences of reduced SERCA2a levels (expected to 
cause a partial loss of function of the SERCA pump) need to be performed to 
examine whether there is diastolic dysfunction in GSDs. This could be 
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accomplished by Tissue Doppler Echocardiography, which can detect subtle 
or early cardiac diastolic dysfunction (Chetboul et al., 2006).  
Summary 
This chapter describes genetic and molecular studies of the GSD model of 
inherited ventricular arrhythmias. Genome-wide linkage analysis was 
performed but failed to definitively detect genomic region(s) associated with 
ventricular arrhythmias in young GSDs. In a complimentary candidate gene 
approach, the expression level of ATP2A2 (SERCA2a) was found to be 
significantly inversely correlated with the severity of arrhythmias in GSDs. This 
work suggests that the mechanism underlying ventricular arrhythmias in GSDs 
involves abnormal calcium handling due to reduced levels of SERCA2. While 
future genetic studies are needed to identify the causative gene(s), my work 
indicates that genes upstream of ATP2A2 expression might act as modifiers 
that modulate the disease severity in GSDs. 
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CHAPTER 3 
DEVELOPMENTAL CARDIAC DEFECTS IN DARK-LIKE MICE 
Introduction 
Over the last century, the mouse has been developed into a useful model 
organism for genetic and biomedical research. Pigmentation disorders were 
one of the earliest genetic diseases studied in the mouse model system. 
Today, over 130 genes and 1,000 alleles have been identified that regulate 
pigmentation phenotypes (Steingrimsson et al., 2006). Mammals make two 
types of pigment: black/brown eumelanin and yellow/red pheomelanin. In 
many mammals, the “normal” coat hairs are black with a subapical band of 
yellow that results when hair follicle melanocytes switch between the 
production of eumelanin to pheomelanin during the mid-portion of the hair 
growth cycle, then back again. This phenotype is referred to as agouti. The 
switch from synthesis of eumelanin to pheomelanin is controlled by a number 
of gene products, including the melanocortin-1 receptor (MC1R) and its two 
ligands, alpha-melanocyte-stimulating hormone (α-MSH) and agouti signaling 
protein (ASP). Activation of MC1R via binding of the agonist α-MSH or 
constitutive basal activity causes an increase in intracellular cyclic adenosine 
monophosphate (cAMP) levels to result in the production of eumelanin. ASP 
acts as an inverse agonist and when it binds MC1R, cAMP levels are reduced 
and pheomelanin is produced (Figure 3.1).  
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Figure 3.1. Basic pigment-type switching in mice. Constitutive activity 
and/or binding of the agonist α-MSH to the MC1R results in increased 
intracellular cAMP levels, which leads to the synthesis of black/brown 
eumelanin. Binding of the inverse agonist agouti (ASP) to the MC1R results in 
reduced levels of cAMP and synthesis of red/yellow pheomelanin. Mice 
lacking agouti or with constitutively active/hyperactive MC1R are black, while 
mice that ubiquitously express agouti or are homozygous for a loss-of-function 
allele of Mc1r are completely yellow.  
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Loss-of-function of Mc1r (Mc1re, previously called recessive yellow, e) gives 
rise to mice with completely yellow fur, while gain-of-function (i.e. Mc1rE-tob or 
Mc1rE-so) results in mice with completely black hair. ASP is encoded by the a 
(agouti) locus. A gain-of-function mutation that results in ubiquitous over-
expression of ASP (lethal yellow, Ay) results in mice that are completely yellow, 
while loss-of-function mutations produce mice with solid black hairs.  
Pigmentation mutations often have pleiotropic effects on multiple body 
systems. Coat color is a visible marker, which helps identify genes that may 
cause underlying systemic diseases. Studying pigmentation mouse mutants 
often provides valuable insights into the function of genes with diverse 
physiological functions and the related systemic disorders, in addition to 
pigment-type switching. Loss-of-function mutations in genes contributing to the 
production of eumelanin and pheomelanin, such as attractin (Atrn) or 
mahogunin ring finger-1 (Mgrn1), have been well studied in the context of 
developmental defects and systemic organ dysfunctions.  
Atrn encodes a type I transmembrane protein with a short cytoplasmic tail and 
a large ectodomain. Mice with loss of function mutation in Atrn have 
phenotypes that include dark coat color and vacuolation of the central nervous 
system and testes (Bronson et al., 2001; Cota et al., 2008; He et al., 2001; 
Kuramoto et al., 2001; Miller et al., 1997). The neurological phenotype is 
associated with tremor, hyperactivity, and reduced body weight and adiposity 
(Gunn et al., 2001). While the function of ATRN in the nervous system remains 
unknown, in pigment-type switching it has been implicated as a low-affinity 
accessory receptor for ASP (He et al., 2001). It was also observed that some 
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mice homozygous for loss of both Atrn and its homolog, Atrnl1 (Atrnmg-3J/mg-3J; 
Atrnl1tar/tar double mutants) develop a progressive adult-onset cardiomyopathy 
(Walker et al., 2007).  
MGRN1 is a RING finger domain-containing protein with ubiquitin ligase (E3) 
activity (He et al., 2003; Kim et al., 2007). Mgrn1 null mutant mice show 
multiple phenotypic defects including completely black coat hairs, progressive 
adult-onset neurodegeneration associated with mitochondrial dysfunction, 
abnormal patterning of the left-right body axis that leads to congenital heart 
defects such as septal and AV cushion defects, reduced viability, and 
craniofacial defects (Cota et al., 2006; He et al., 2003; Jiao et al., 2009; Sun et 
al., 2007). Approximately 50% of Mgrn1 null mutants die before or shortly after 
birth. A very small number of surviving null mutants display complete situs 
inversus, and in-situ hybridization analysis detected abnormal expression of 
genes involved in left-right patterning. Histological analysis for mid-to-late 
gestation Mgrn1 mutant embryos revealed a high frequency of congenital 
heart defects, including atrial septal defects, ventricular septal defects, and 
atrio-ventricular cushion defects (Cota et al., 2006).  
Cardiocutaneous syndromes have also been identified in human diseases. 
Multiple lentigines syndrome (MLS) manifests generalized lentiginosis 
(lentigines are dark or brown macules characterized by accumulation of 
melanin granules), hypertrophic cardiomyopathy, atrial septal defects, 
malignant arrhythmias resulting in sudden cardiac death and genital 
hypoplasia (Abdelmalek et al., 2002). Patients carry a missense mutation in 
Ptpn11 gene which encodes Src homology 2 domain-containing protein-
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tyrosine phosphatase (Lehmann et al., 2009). A common embryological origin 
of melanocytes and cardiomyocytes might explain the relationship between 
pigment phenotypes and cardiac defects (Jiang et al., 2000). Derivatives from 
neural crest cells give rise to many different cell types such as cardiomyocytes, 
melanocytes, bones, connective tissues and neurons. Coordinated neural 
crest cell migration is critical in order to accomplish successful organ 
development and function. Thus, mutations in genes that regulate neural crest 
migration, survival, proliferation and/or differentiation can affect multiple neural 
crest lineages to cause pleiotropic phenotypes in different tissues or organs 
simultaneously. 
Mice homozygous for the recessive dark (da) mutation were identified in the 
1950’s and reported to have dark dorsal hairs and reduced growth rate and 
fertility (Falconer, 1956). This mutant appears to be extinct, but a new 
spontaneous mouse mutant with a similar phenotype that maps to the same 
general chromosomal location (proximal chromosome 7) arose at The Jackson 
Laboratory in the 1980’s. Since da is extinct, an allelism test could not be 
performed and the new mutant was named dark-like (dal) (Harris, 2003). Mice 
homozygous for the dal mutation were reported to be easily distinguished from 
wild-type mice by 14 days of age due to their small body size and dark dorsal 
hairs, although the coat color phenotype was less apparent as animals aged. 
Genetic crosses were used to investigate the epistatic relationships between 
dal and other pigment-type switching genes (Cota et al., 2008). Double 
mutants were generated by crossing dal mutants (dark coat color) to Ay and 
Mc1re mutants. Ay mice homozygous for dal had brown backs and yellow 
63 
 
bellies, while Mc1re/e; dal/dal mice were yellow. These observations place dal 
downstream of agouti transcription and upstream of Mc1r.  
In addition to coat color, other phenotypes have been reported in dal mutants. 
Male and female dal mice were reported to breed normally until 5 months of 
age, but by 7 months of age, the reproductive performance of both sexes was 
reduced. Preliminary studies identified reproductive degeneration 
characterized by the absence of follicles and presence of many corpora lutea 
in 7-month old females and mild testicular degeneration with increased Leydig 
cells in 7-month old males (Harris, 2003). Studies to further analyze the 
reproductive degeneration in male dal mutant mice revealed vacuoles in dal 
mutant testis and reduced serum testosterone levels. Mating dal mutants to 
Atrn null mutants revealed an additive effect of these mutations on 
pigmentation and testicular and CNS vacuolation (Cota et al., 2008). Azouz 
and colleagues previously reported that loss of lipid raft domains was 
correlated with vacuolation in Atrn mutant brains (Azouz et al., 2007) and a 
similar phenomenon was observed for lipid rafts in the testes of dal mutant 
mice. These observations suggest that dal and Atrn act in a common pathway 
in pigment-type switching and vacuolation.    
In performing the genetic crosses described above, it was noted that dal/dal 
pups were observed at lower than expected proportions and those that were 
born were more likely to be very small and often died before weaning (Teresa 
Gunn, personal communication). As congenital heart defects are a common 
cause of embryonic lethality and growth retardation, I hypothesized that the 
dal gene plays a pivotal role in cardiac development. A comprehensive 
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histological analysis revealed multiple heart defects including thickened 
cardiac ventricular walls, which I confirmed to be the result of developmental 
cardiac hypertrophy. I identified the gene mutated in dal mice as peptidase d 
(Pepd), which encodes the enzyme prolidase, and demonstrated that loss-of-
function of Pepd in zebrafish also causes pigmentation and cardiac defects. 
Prolidase is involved in collagen biosynthesis and recycling, and I 
demonstrated that disrupted integrin signaling underlies the cardiomyocyte 
hypertrophy observed in dal mutant embryos. This study introduces the dal 
mutant mouse as a novel model for studying myocardial development and the 
transition from proliferative to hypertrophic cardiomyocyte growth. It also 
presents the first examination of the function of Pepd in regulating the 
extracellular collagen matrix, integrin signaling and cytoskeletal organization in 
cardiomyocytes.   
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Materials and Methods 
Mice 
All mice were maintained under standard conditions in the Transgenic Mouse 
Core and East Campus Research Facilities at Cornell University. C3H/HeJ 
mice were originally obtained from the Jackson Laboratory (Bar Harbor, Maine) 
and maintained by brother-sister inbreeding. Mice carrying the pCAGGS-
GCaMP transgene were generously provided by Dr. Michael Kotlikoff. 
Homozygous CBA/J-dal/dal mice were obtained from The Jackson Laboratory. 
The reproductive performance of CBA/J-dal/dal mice was very poor, the 
darkened coat color phenotype was not very strong and tended to disappear 
by the time mice were 6 months of age, and other pigment-type switching 
mutations in the Gunn laboratory are generally studied on the C3H/HeJ strain 
background (as it accentuates darkened coat color phenotypes). For these 
reasons, CBA/J-dal/dal mice were mated to C3H/HeJ mice to generate 
heterozygous F1 progeny. Brother-sister pairs were set up from this and 
subsequent generations to produce intercrossed C3.CB-dal/dal and dal/+ pups; 
mice from generations F5-7 were used in the studies described below. Some 
C3.CB F1 animals were also backcrossed to C3H/HeJ mice for up to 6 
generations (N6) to create incipient congenic mice that carry >98% of their 
genome from the C3H/HeJ background. The pre- and peri-natal lethality of 
these mice was much higher than that observed in the CBA/J-dal/dal or 
intercrossed C3.CB-dal/dal, consistent with anecdotal reports that heart 
defects are often more severe on the C3H/HeJ strain background.   
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F1 progeny generated by breeding a female pCAGGS-GCaMP mouse to a 
male F7 C3.CB-dal/dal mouse were backcrossed to F7 C3.CB-dal/dal mice. 
From this cross, female dal/dal mice carrying the pCAGGS-GCaMP transgene 
were used for timed-matings with F7 C3.CB-dal/dal males to produce dal/dal; 
pCAGGS-GCaMP(+) embryos. Genotypes of these mice and embryos were 
confirmed by PCR analysis as described below. 
C3H/HeJ and C3.CB-dal/dal embryos for phenotypic analyses were collected 
from timed pregnancies. Male C3.CB-dal/dal mice were caged individually and 
given 2-3 mature (≥6 week-old) female mice. Females were checked for 
copulation plugs between 9 and 10 AM every day to determine whether mating 
had occurred. Noon of the day of the plug was considered day 0.5 of 
embryonic gestation (E0.5). Mice were euthanized by carbon dioxide 
inhalation, the uterus removed and embryos dissected under phosphate 
buffered saline (PBS). 
Mouse genotyping 
Once the dal mutation was identified, mice and embryos were genotyped by 
PCR amplification using forward primer AGCGCATCGATGAACCTG and 
reverse primer TCCAAGAGGTGGTCAATGAA under the following conditions: 
initial 5 minute denaturation at 95°C, then 35 cycles at 95°C for 30 seconds, 
57°C for 30 seconds, and 72°C for 30 seconds, followed by a final extension 
at 72°C for 10 minutes. Products were separated on 5% low melting Nusieve 
agarose gels. Mice carrying the pCAGGS-GCaMP transgene were identified 
by performing PCR using forward primer AAGGGCGAGGAGCTGTTCA and 
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reverse primer CGATCTGCTCTTCAGTCAGTTGGT under the same 
amplification conditions described above.  
Positional cloning 
In order to identify the dal gene by position cloning, a mapping cross was 
established by mating a CBA/J-dal/dal male mouse to CAST/EiJ female mice. 
CAST/EiJ is a wild-derived inbred strain that has a high degree of genetic 
variation relative to C3H/HeJ and CBA/J mice. F1 hybrid males and females 
were mated to CBA/J-dal/dal or C3.CB-dal/dal (N3F1, F5-7) mice to produce the 
first generation interspecific backcross (BC1) population. A second generation 
BC2 population was also generated by mating some non-recombinant agouti 
(dal/+) BC1 mice to F5 or F7 C3.CB-dal/dal mice. At 14-21 days of age, the 
genotype of BC pups at the dal locus was inferred by examining coat color (dal 
vs. agouti). DNA was isolated from tail tips using a standard protocol with 
proteinase K digestion, chloroform extraction and ethanol precipitation.  
DNA from the parental strains, F1 hybrids, BC1 and BC2 pups was used as 
template for polymerase chain reaction (PCR) amplification of D7Mit114 and 
D7Mit228, which are polymorphic among CAST/EiJ, CBA/J and C3H/HeJ, and 
encompass the candidate interval defined by Harris et al. (D7Mit294 to 
D7Mit247) (Harris, 2003). BC animals with recombination events between 
D7Mit114 and D7Mit228 were genotyped for 11 informative microsatellite 
markers (D7Mit267, D7Mit210, D7Mit246, D7Mit344, D7Mit155, D7Mit79, 
D7Mit269, D7Mit225, D7Mit78, D7Mit309 and D7Mit25) that lie between 
D7Mit114 and D7Mit228 to refine the map position of recombination 
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breakpoints. Primer sequences for these markers are listed in Table 3.1. All 
amplifications were performed under the same conditions: initial 5 minutes 
denaturation at 95°C, then 35 cycles of 95°C for 30 seconds, 55°C for 30 
seconds, and 72°C  for 30 seconds, followed by a final extension at 72°C  for 
10 minutes. Products were separated on 3% Nusieve, 1% agarose gels.  
Total RNA was extracted from the hearts of E15.5 dal/dal and C3H/HeJ 
embryos, and also from testis of 3-month old homozygous dal/dal and 
C3H/HeJ mice using Trizol (Invitrogen, Carlsbad, CA). Genomic DNA from 
CBA/J, homozygous dal/dal and heterozygous dal/+ mice was purchased from 
the DNA Resource at The Jackson Laboratory. Total RNA was transcribed into 
cDNA using ABI High Capacity cDNA Kit (Applied Biosystem, Foster city, CA). 
Overlapping primers were designed to amplify the cDNAs of candidate genes; 
the same primers were used to sequence the products (Table 3.2). 
Amplification conditions were as follows: initial 5 minutes denaturation at 95°C , 
then 35 cycles of 95°C  for 30 seconds, 58°C  for 30 seconds, and 72°C  for 1 
minute, followed by a final extension at 72°C  for 10 minutes. PCR products 
were cleaned by incubating them with 2 μl ExoSAP-ITTM reagent (USB, 
Cleveland, OH) at 37°C for 15 minutes followed by 80°C for 15 minutes. Five 
microliters of treated product was used in each sequencing reaction. All PCR 
products were sequenced from both directions with ABI 3730 sequencer 
(Applied Biosystem) at the Sequencing Core Facility in the BioResource 
Center at Cornell University.  
Once the Pepd deletion mutation was identified in the cDNA of dal mutants, it 
was confirmed by PCR amplification and sequencing of this region from  
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Table 3.1. Primer sequences for microsatellite markers across the dal 
candidate interval 
marker Primer sequence 
D7Mit114 F-TGGAGGGGAAATGGCAAG R-ACCTTCTATTTCTTGCCTATGCC 
D7Mit267 F- CTCTTTCTGTTACATGGTTAGATTTCC R- AAAGACAGTTGAAGTTGACTTCTGG 
D7Mit210 F-TCCCCAGGAAAGTGTTTGTC R-TTAAGCCCTTTAGATATACAGGTGTG 
D7Mit246 F-CACACAAAGCCGCAGTTCTA R-TTGTTACGTGGCCTAGATTGG 
D7Mit344 F-CAAGACCAGCCTGGGATG R-TACAAGCATGCAGGCAGAAC 
D7Mit155 F-GTTGGAGAAATGACACCATGG R-ACTTTACACACTGATCACTTTTCAGC 
D7Mit79 F-GGTGCAGGAGGGACACTTAA R-CACCACACCCAGCAGATTTA 
D7Mit269 F-ATGGTGGCAGGTGCATCT R-TCTTTCAACCACTTATTGCGG 
D7Mit225 F-TTAACCTGGACTGTACAAAGAGACC R-GAGATGAAGGGAGATGGAAGG 
D7Mit78 F-ATGACACCCAAGGGCTAGC R-ATAAAGCCCAGCATGCTTTG 
D7Mit309 F-TGATAAGGACCCTACAAGCACC R-CACAGAGATGGACAGATACAGACA 
D7Mit25 F-AGGGGCACATGTTCAACTATG R-GGTTGTTTCCAGCTTTGGG 
D7Mit228 F-ATTCTTGGCCTTTTCTTGTAACA R-AAACCTCCACACTGACTTCCA 
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1: Peptidase D 
2: Density lipoprotein receptor-related protein 3 
3: Coiled-coil domain containing 123 
4: CCAAT/enhancer binding protein (C/EBP), gamma 
* Superscript t# identifies alternatively spliced transcripts.  
  
Table 3.2. Primers used to amplify candidate gene cDNAs 
Gene name Primer name* Primer sequence 
Pepd1 
Pepd-1Ft1 GAGTGAACATGGCGTCCAC 
Pepd-1Rt1 GCAGGTGATGTCAGAAGCAA 
Pepd-2Ft1 CAATGACCGGACGATCAAG 
Pepd-2Rt1 TTCGATTTCCTCCACAGTCC 
Pepd-3Ft1 TTCATTGACCACCTCTTGGA 
Pepd-3Rt1 GCAAATTCCATTCTGCATGTT 
Pepd-1Ft2 TCTCCCTGGGGAATGAGAC 
Pepd-1Rt2 GGGAAGGAGCAGGTGATGT 
Pepd-2Ft2 CAATGACCGGACGATCAAG 
Pepd-2Rt2 TTCGATTTCCTCCACAGTCC 
Pepd-3Ft2 TGGAGCCAGGCATCTACTTC 
Pepd-3Rt2 GCAAATTCCATTCTGCATGTT 
Lrp32 
Lrp3-1Ft1 AGCGACGCACCCTCGTAG 
Lrp3-1Rt1 GACCAGCACTGCGAGCAC 
Lrp3-2Ft1 CTTCGGACCTTCACTGCAC 
Lrp3-2Rt1 ACAGACAGGGGCAATGAGAC 
Lrp3-1Ft2 AGCGACGCACCCTCGTAG 
Lrp3-1Rt2 GACCAGCACTGCGAGCAC 
Lrp3-2Ft2 CTTCGGACCTTCACTGCAC 
Lrp3-2Rt2 CAGAAGGGCCTCATCATCAC 
Ccdc1233 
Ccdc-1F CTAGGCTGTGGGGAGCTGT 
Ccdc-1R AAGCCTTTTCCGTCTCCTTC 
Ccdc-2F CCAAAGAAAAGTTTGCGGAGT 
Ccdc-2R AGCAGGCTCTTCTTCTGCAC 
Ccdc-3F TGGATAGCAAGATCGCAGTG 
Ccdc-3R TCCCTTGCCTATGACACTCA 
Cepbg4 
Cepbg-1F GCGCAGGTACATGTGAAGATT 
Cepbg-1R TCCAGGAATTTTGTTTTAACGAT 
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5: G patch domain containing 1 
6: Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 
7: CCAAT/enhancer binding protein (C/EBP), alpha 
  
Table 3.2. Primers used to amplify candidate gene cDNAs 
(Continued) 
Gene name Primer name Primer sequence 
Gpatch5 
Gpatch-1Ft1 AGTGACAGCGACGAGGATCT 
Gpatch-1Rt1 GAGCTGTCCAGCCATAGAGG 
Gpatch-2Ft1 AGAAAACTGGGCATTTCTGG 
Gpatch-2Rt1 ATCTTCACAGCCGACTGCTT 
Gpatch-3Ft1 CAAGGAGGAGGAGGATTCAG 
Gpatch-3Rt1 CAGCCTCCTGAGAGCCTTTA 
Gpatch-4Ft1 ACGCCCAGACACGACTGTA 
Gpatch-4Rt1 TCCTTCTAACATGGACTGAAGTT
Gpatch-1Ft2 AGTGACAGCGACGAGGATCT 
Gpatch-1Rt2 GAGCTGTCCAGCCATAGAGG 
Gpatch-2Ft2 AGAAAACTGGGCATTTCTGG 
Gpatch-2Rt2 ATCTTCACAGCCGACTGCTT 
Gpatch-3Ft2 CAAGGAGGAGGAGGATTCAG 
Gpatch-3Rt2 CAGCCTCCTGAGAGCCTTTA 
Gpatch-4Ft2 ATCTTCGCCAGTTCCTCTGA 
Gpatch-4Rt2 TCAGCCATCACATGATTTTG 
Chst86 
Chst8-1F GCGGGGAAGAGACAGGAC 
Chst8-1R CCTGCCTTGGGTACTTCACA 
Chst8-2F CGCACCATGGACAGTCGT 
Chst8-2R AAGTCGTAGGTTCGCTGTCG 
Chst8-3F CTTCTTCCTGCGTCTCATCC 
Chst8-3R CCCTGGGTCATAGAAAAGCA 
Cebpa7 
Cebpa-1F GAGCCAGTTGGGGCACTG 
Cebpa-1R GCTGTTCTTGTCCACCGACT 
Cebpa-2F CCACTTGCAGTTCCAGATCG 
Cebpa-2R CGGGATCTCAGCTTCCTGTA 
Cebpa-3F CAGGGCAGGAGGAAGATACA 
Cebpa-3R AAGAGAAGGAAGCGGTCCAG 
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8: Potassium channel tetramerisation domain containing 15 
9: Rhophilin, Rho GTPase binding protein 2 
10: Solute carrier family 7 (cationic amino acid transporter), member 10 
 
Table 3.2. Primers used to amplify candidate gene cDNAs 
(Continued) 
Gene name Primer name Primer sequence 
Kctd158 
Kctd15-t1-1Ft1 CTTGGAGAAGCGGGTCAAT 
Kctd15-t1-1Rt1 CAGCCAGGGGAGACACAG 
Kctd15-t1-2Ft1 ATGGAAGCCTAGATGCCTCA 
Kctd15-t1-2Rt1 CCCAGCAGAGGACGCTATAC 
Kctd15-t1-3Ft1 GTGTCCACGGAAGGACTGTT 
Kctd15-t1-3Rt1 GCGTTCTTTATGGCATGAACC 
Kctd15-t2-1Ft2 GGGGGCGAGAGAGAAAGTAA 
Kctd15-t2-1Rt2 CAGCCAGGGGAGACACAG 
Kctd15-t2-2Ft2 ATGGAAGCCTAGATGCCTCA 
Kctd15-t2-2Rt2 CCCAGCAGAGGACGCTATAC 
Kctd15-t2-3Ft2 GTGTCCACGGAAGGACTGTT 
Kctd15-t2-3Rt2 GCGTTCTTTATGGCATGAACC 
Kctd15-t3-1Ft3 GCGCTCGTCCAGGAAATG 
Kctd15-t3-1Rt3 CAGCCAGGGGAGACACAG 
Kctd15-t3-2Ft3 ATGGAAGCCTAGATGCCTCA 
Kctd15-t3-2Rt3 CCCAGCAGAGGACGCTATAC 
Kctd15-t3-3Ft3 GTGTCCACGGAAGGACTGTT 
Kctd15-t3-3Rt3 GCGTTCTTTATGGCATGAACC 
Rhpn29 
Rhpn2-1F TCCAGGCACAGAAACAGTCA 
Rhpn2-1R GAAGCCTCTGGATGTTGGAG 
Rhpn2-2F TTTATTGAGGCCCATGGTGT 
Rhpn2-2R ATCATCGCCATCATCTAGCC 
Riken clone 
C28005212 
Riken clone-1F CTTGCGAGAGCTTGTCCTCT 
Riken clone-1R GAGCTAGGTGGGAAGGATGG 
Riken clone-2F ATGTTCTGTCCCCTCACAGG 
Riken clone-2R GAAGGTGGGCAAGAACTGTC 
Slc7a1010 
Slc7a10-1F GGTAGCGCAGGGAACTGG 
Slc7a10-1R CCTGGATGAGGTGAACAGGT 
Slc7a10-2F GAGAAGCTGCTGGGCTACTTT 
Slc7a10-2R CAGCAACAACCAGCCCTGT 
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genomic DNA using forward primer AGCGCATCGATGAACCTG and reverse 
primer TCCAAGAGGTGGTCAATGAA.  
Quantitative real time PCR 
Wild type and dal/dal embryos were dissected in ice-cold PBS. Total RNA 
from each embryonic heart was extracted using Trizol (Invitrogen) according to 
the manufacturer instructions, and 10 nanogram of total RNA was reverse 
transcribed in a final volume of 20 μl using ABI High Capacity cDNA Kit. All 
PCR reactions were performed using the ABI 3700 Real Time System. Each 
sample was analyzed in triplicate on the same plate. PCR reactions containing 
1 μl cDNA template, 10mM of each primer and 2X SYBR green PCR master 
mix (Applied Biosystems) were incubated at 50°C for 2 minutes, then 
denatured for 10 minutes at 95°C. Following initial incubation, 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute were performed. Primer 
sequences are listed in Table 3.3. The expression levels for genes of interest 
(Pepd, ANP, BNP) normalized to the housekeeping gene GPI were 
determined using comparative Ct method of relative quantification (Livak and 
Schmittgen, 2001). The RQ value of each gene of interest was expressed as 
the fold change relative to that of endogenous control gene. Student’s t-test 
was utilized to compare the mean difference in transcript level between 
controls and dal/dal mutants.  
Histological studies  
Embryos were harvested in ice-cold PBS, fixed in 10% buffered formalin for at 
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1: Peptidase D 
2: Glucose-6-Phophate Isomerse 
3: Atrial natriuretic peptide 
4: Brain natriuretic peptide 
 
least 12 hours, then dehydrated through an ethanol series and cleared in 
xylene. Prepared embryos were placed in molds, paraffin-embedded, and 
allowed to set in cold plates. Six to ten micrometer (μm) transverse serial 
sections were made, mounted on Superfrost slides, processed for dewaxing, 
stained with hematoxylin and eosin (H&E) , then mounted in aqueous media 
(Permount, Invitrogen) using standard protocols. Mounted slides were dried at 
room temperature overnight and viewed and photographed at 10X 
magnification on a Leica DMRE fluorescent microscope (Leica, Germany).  
Picrosirius red staining is a commonly used method to detect extracellular 
collagen. Five hearts (each) from 2 month-old dal/dal and C3H/HeJ mice were 
collected, embedded in paraffin and sectioned at 7 μm. Slides were stained 
Table 3.3. Primer sequences used for quantitative real time PCR 
Gene name Primer sequence 
Pepd1 F- GAAGGCCATCTACGAAGCAG R- CTCCAGGTGGATACGGTCAG 
GPI2 F- CAACTGCTACGGCTGTGAGA R- CTTTCCGTTGGACTCCATGT 
ANP3 F- CCTTGATGTCTTTGGGGAGA R- GATTTGGGGGTTCTCGGTAT 
BNP4 F- TGCTTTGGGCACAAGATAGA R- AGACCCAGGCAGAGTCAGAA 
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with Picrosirius red solution (0.1% Sirius Red F3BA, Sigma, St.Louis, MO) in 
saturated aqueous picric acid, rinsed in 0.01N HCl for 2 minutes, dehydrated, 
and mounted with cover slips. Mounted slides were dried at room temperature 
overnight and viewed and photographed at 20X magnification on a Leica 
DMRE fluorescent microscope (Leica, Germany).  
BrdU incorporation assay  
Cell proliferation was assayed on paraffin-embedded sections of E12.5 
embryos using 5-bromo-2’-deoxy-uridine (BrdU). One hour prior to euthanasia, 
pregnant mice were injected peritoneally with 100 μg BrdU (Invitrogen) per 
gram (g) of body weight diluted in PBS. Embryos were fixed, embedded in 
paraffin and sectioned, as described above. Sections were deparaffinized in 
xylene, rehydrated through an ethanol series, washed in PBS, denatured in 2N 
HCL for 30 minutes at room temperature, neutralized by washing in PBS, and 
incubated in blocking solution (1% bovine serum albumin (BSA), 0.2% low fat 
milk and 0.3% Triton X-100) for 15 min at room temperature. Mouse 
monoclonal anti-BrdU antibody (BrdU Staining Kit, Invitrogen) diluted 1:100 in 
blocking solution was added and slides were incubated with Cy3-conjugated 
anti-mouse antibody diluted 1:1000 in blocking solution at room temperature 
for 1 hour, washed in PBS, and mounted with Paramount mounting media 
(Invitrogen). Sections were examined and photographed digitally using a Leica 
DMRE fluorescent microscope (Leica, Germany). The number of BrdU positive 
cells was quantified within the interventricular septum under 100X 
magnification from a minimum of three separate areas and within endocardial 
cushion area under 40X magnification for each wild type and dal/dal 
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embryonic heart. The proportion of BrdU positive cells was analyzed using z-
test with significance set at p<0.05. 
Cardiomyocyte isolation 
Embryonic cardiomyocytes were isolated from E15.5 dal homozygous mutant 
and C3H/HeJ control embryos. Hearts were visualized and harvested through 
an incision through the anterior chest wall, placed on ice and washed in ice-
cold PBS. Ventricular tissues were selectively separated. The ventricles were 
dissociated by serial enzymatic digestion with collagenase B (Roche, 
Germany) in a shaking water bath at 37°C and 100 rpm. The isolated cells 
were immediately collected by centrifugation at 1400 rpm and resuspended 
into culture medium containing DMEM (Cellgro, Manassas, VA), 20% FCS and 
100 μg/ml penicillin/streptomycin (Cellgro). Suspended cells were seeded onto 
culture plates and maintained in a humidified atmosphere of 5% CO2 at 37°C 
overnight. All pictures of beating individual cardiomyocytes were taken under 
the same magnification. Cell surface area was measured using polygon 
selections in the ImageJ software program. Parameter adjustments with 180 of 
distance in pixels and 20 of known distance were set for all pictures to 
synchronize the scale between each picture. 
Actin cytoskeletal staining and confocal microscopy analysis 
Cardiomyocytes isolated from E15.5 dal/dal and C3H/HeJ embryonic hearts 
(as described above) were grown on poly-L-lysine-coated glass coverslips 
overnight. Cells were then washed with ice-cold PBS, fixed with 4% 
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paraformaldehyde in PBS, permeabilized with Triton X-100 in PBS (0.1%) for 
30 minutes and treated with a blocking solution of 7% BSA in PBS for 30 
minutes at room temperature. For staining of polymerized actin filaments, cells 
were incubated with alexa 647-conjugated phalloidin (Alexa Fluor 647, 
Invitrogen) for 1 hour and then rinsed in PBS. Coverslips were mounted onto 
microscope glass slides with Vectashield anti-fade mounting medium. 
Phalloidin labeling was visualized using an Olympus IX70 confocal imaging 
system (Olympus, Center Valley, PA) and images captured as a stacked 
series (1 mm Z steps). Image-acquisition settings (laser intensity, iris size, 
magnification, and amplifier gain) were maintained constant for all images to 
allow for comparisons between groups. The intensity of alexa-phallodin-
stained actin was determined using Fluoview v5.0 software (Olympus, 
Germany).  
In vivo calcium imaging 
E12.5 embryos were collected from pregnant C3.CB-dal/dal; pCAGGS-
GCaMP(+) females. Embryos were maintained in embryo holding solution 
(NaCl 136mM, KCl 5.4mM, MgCL2·6H2O 1mM, NaH2PO4 0.33mM, 
CaCl2·2H2O 2.5mM, Glucose 10mM and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 10mM) on ice throughout the study. After 
exposing an embryonic heart via opening the chest cavity, fluorescence of 
calcium transients was imaged using an Olympus MVX10 inverted microscope 
(Olympus, Germany) and intensified using a charge-coupled device camera 
(Andor Technology, UK). Image acquisition and data analysis were performed 
using Metafluor 5.0 and ImageJ software programs. After image analysis was 
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completed, each embryo was fixed in 10% buffered formalin for histological 
analysis (following the protocol described above) in order to examine the 
correlation between calcium transients and cardiac structure.  
Antisense morpholino oligo microinjection 
An antisense morpholino oligonucleotide [5’-
ACACCCTACACAACACACAGATGAG-3’] that specifically binds to the splice 
acceptor sequence of exon 20 [5’-ctcatctgtgtgttgtgtagGGTGT-3’; intronic 
sequences in lower case, exonic sequence in upper case letters] of the 
zebrafish Pepd gene was designed and designated as Pepd_MO. A standard 
control morpholino [5’-CCTCTTACCTCAGTTACAATTTATA-3’] against a 
random sequence not present in the zebrafish genome was purchased (Gene 
Tools, Philomath, OR) and designated as Control_MO. Each morpholino 
(Pepd_MO and Control_MO) was injected into the yolk sac of at least 20 wild-
type embryos from 7 different clutches on different days. Embryos at the 1- or 
2-cell stage (when the chorion is intact) were injected with 0.5 mM of 
morpholino oligos under the settings of 3 msec injection time and 30 mmHg 
injection pressure. Injected embryos were raised at 28.5°C to 5 days post-
fertilization (dpf), by which time cardiac development is largely complete 
(Sprague et al., 2001). Successful pre-mRNA modification was monitored by 
RT-PCR across exon 20 using forward primer GGGGTGAAGTGGACAGACAT 
(in exon 19) and reverse primer TTGGACTGAAGGGTTTGGAC (in exon 21) 
using total RNA extracted from morpholino-injected embryos using Trizol 
(Invitrogen) as template. Embryos were examined under the light microscope 
for gross phenotypes, particularly body size and pigmentation. In order to 
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evaluate myocardial development and ventricular wall thickness, Pepd_MO 
and Control_MO were injected into the yolk sac of transgenic zebrafish 
embryos carrying a cardiac myosin light chain promoter-driven green 
fluorescent protein transgene (CMLC-GFP), which drives GFP expression in 
the heart. At 5 days post-injection, embryonic hearts were examined by 
confocal microscopy (Axiovert 200M, Zeiss, Germany) to image cardiac GFP 
expression. Images were analyzed using the LSM510 Meta software program.  
Western blotting 
Hearts from E15.5 dal/dal and C3H/HeJ embryos were collected, washed in 
PBS, and homogenized in RIPA buffer (50mM Tris HCl pH7.4, 150mM NaCl, 
2mM EDTA, 1% NP-40, 0.1% SDS) containing Complete protease inhibitor 
(Roche, Germany) using a polytron homogenizer. Phosphatase inhibitor 
(Invitrogen) was added to lysates when phospho-specific antibodies were 
used for western blotting. Homogenates were cleared by centrifugation at 
12000 rpm for 5 minutes at 4°C. The supernatant was collected and stored at  
-80°C. Protein concentrations were determined by BCA protein assay (Pierce, 
Rockford, IL). Equal amounts of protein lysates (15 μg for total protein and 300 
μg for phosphorylated protein assays) were mixed with 2X SDS buffer (125 
mM Tris-HCl, 10% glycerol, 10% SDS, 130 mM DTT), incubated at 70°C for 5 
minutes and separated on 4% stacking, 8% SDS polyacrylamide gels. 
Proteins were transferred to Immobilon P membrane (Millipore, Bedford, MA) 
at 0.5 mA for 3 hours. Successful transfer was verified by Ponceau S staining. 
Blots were blocked in 5% milk in Tris-Tween Buffered Saline (TTBS) buffer for 
an hour at room temperature and incubated with anti-mouse or rabbit primary 
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antibody in TTBS at 4°C overnight. After washing three times (10 min each), 
blots were incubated in horseradish peroxidase (HRP)-conjugated anti-mouse 
(cat#:554002, BD Transduction Laboratories) or anti-rabbit secondary 
antibody in TTBS for 50 min at room temperature followed by three 15 min 
washes in TTBS. Antibody signal was detected by chemiluminescence (ECL 
Western Blotting Detection Reagent, Amersham, UK) and visualized using the 
Versadoc Imaging system (Bio-Rad, Hercules, CA). Protein signal intensity 
was quantified using ImageJ software (NIH) and the mean values analyzed by 
Student’s t-test. Differences between mean values was considered statistically 
significant at p<0.05.  
Primary antibodies used in the present study were against focal adhesion 
kinase (FAK) (cat#:3285, Cell Signaling Technology, Danvers, MA), phospho-
FAK (cat#:3283, Cell Signaling Technology), Src (cat#:2109, Cell Signaling 
Technology), phospho-Src (cat#:2101, Cell Signaling Technology),  Paxillin 
(cat#:610568, BD Transduction Laboratories, San Jose, CA), F-Actin 
(cat#:RDI-PRO61075, Fitzgerald, Concord, MA) and SERCA2a (cat#:ab2861, 
Abcam, Cambridge, MA). Membranes were re-blotted with HRP-conjugated 
GAPDH (cat#:ab9482, Abcam) to verify equal protein loading.  
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Results 
Characterization of developmental cardiac phenotypes in dal embryos 
Mice homozygous for the dal mutation had previously been reported to be 
smaller than their wild-type littermates (Harris, 2003). In BC mice generated by 
mating CAST/EiJ x C3.CB-dal/dal F1 mice back to C3.CB-dal/dal mice, the 
average weight of postnatal day 14 homozygous dal mutant pups was 6.2 g 
(n=30), which was significantly less than that of their heterozygous littermates, 
which 9.2 g (n=62) (Figure 3.2). In addition, a high rate of embryonic and 
perinatal lethality had previously been observed for dal/dal animals (Teresa 
Gunn, personal communication). For example, 27% of implantations in litters 
of mid-to-late gestation dal embryos were dead and/or resorbed, and 5.9% of 
surviving embryos were developmentally delayed (small body size relative to 
other littermates) (Table 3.4). As cardiac defects are the most common cause 
of mid-to-late gestation lethality and growth retardation (Takahashi et al., 
2004), I hypothesized that the dal mutation disrupts normal cardiogenesis. I 
performed a comprehensive histological analysis of mid-to-late gestation 
(E12.5, E15.5, and E18.5) dal/dal and control embryos to detect the presence 
and frequency of cardiac structural abnormalities in dal embryos (Table 3.5). 
The most striking cardiac abnormality, observed in 67.6% of dal/dal mutant 
embryos, was a substantially increased thickness of the ventricular wall 
(Figure 3.3). Augmented ventricular thickness was most prominent at the 
interventricular septum. The interventricular septum of dal/dal embryonic 
hearts was significantly thicker (~1.6 fold) than that of controls (p=0.0002, 
Figure 3.4).  
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Figure 3.2. Gross phenotypes of dal mutant mice. (A) Mice homozygous 
for the dal mutation are generally small in size and have dark fur. 
Heterozygotes are indistinguishable from wild-type mice (not shown). (B) In a 
CAST x dal backcross, the mean body weight of two week-old dal/dal mice 
(6.2g) was significantly lower than that of dal/+ mice (9.2g) (*Student’s t-test 
with Mann-Whitney correction : p<0.0001).  
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Table 3.4. Reduced viability in dal/dal mutant embryos 
Stage embryos n 
growth delayed 
n (%) 
dead or resorbed 
n (%) 
E13.5-14.5 89 6 (6.7%) 17 (19.1%) 
E14.5-18.5 63 3 (4.8%) 24 (38.1%) 
Total 152 9 (5.9)% 41 (27.0%) 
Table 3.5. Cardiac structural defects present in dal/dal mutant embryos 
Strain Age Normal thickness Increased ventricular mass 
dal/dal 
  E12.5 (n=9) 3 6 (2ASD, 1 VSD) 
  E15.5 (n=12) 3 9 (1 ASD) 
  E18.5 (n=13) 5 8 (2 ASD) 
C3H/HeJ 
  E12.5 (n=4) 4 - 
  E15.5 (n=5) 5 - 
  E18.5 (n=5) 5 - 
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Figure 3.3. Developmental cardiac defects in dal mutant mice. (A-B) H&E 
stained sections of E12.5 wild-type (A) and dal/dal (B) hearts showed atrial 
and ventricular septal defects (*) and markedly enlarged endocardial cushions 
(black arrow) in dal mutants. (C-D) H&E stained ventricular sections of E16.5 
wild-type (C) and dal/dal (D)hearts showing significantly thickened ventricular 
walls (black arrow) and an atrial septal defect (*) in dal mutants. (E-F) High 
magnification view of ventricular septum of 3-month old wild-type (E) and 
dal/dal (F) mice demonstrating myocytic and myofibrillar disarray in mutant 
hearts (F). 
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Figure 3.4. Interventricular septum is thicker in dal/dal embryonic hearts. 
(A) The thickness at the mid portion of interventricular septum was measured 
(as indicated by green bar). (B) Interventricular septum of dal/dal embryonic 
hearts (38 units) was significantly thicker than that of wild-type embryonic 
hearts (24 units) (* Student t-test p=0.0002).    
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Atrial septal defects (ASD) and/or ventricular septal defects (VSD) were 
observed in 15% of dal/dal mutant embryos (Table 3.5). The endocardial 
cushion area also appeared enlarged in some mid-gestation dal mutant 
embryonic hearts, with no evidence of increased cellular proliferation or 
density (Figure 3.3 and 3.5). Over the course of late pregnancy, however, no 
obvious structural defects such as aplastic or dysplastic valve were seen at 
the AV junction area (Figure 3.6). No anatomical abnormalities were detected 
in the atrial tissue of dal/dal embryos, with atrial wall thickness and chamber 
dimension comparable between wild-type and dal/dal embryos (Figure 3.3). 
High power magnification of the region of thickened ventricles in 3 month-old 
adult dal mice showed a myocytic and myofibrillar disarray (abnormal 
disturbance of normally ordered cardiac cell alignment), which is the 
pathological hallmark of cardiac hypertrophy in humans (Figure 3.3) (Ly et al., 
2005).  
The heart defects observed in dal mutant embryos indicated that the gene 
mutated in these animals plays an important role in myocardial development. It 
was not clear, however, whether the increased ventricular mass reflected an 
increase in the number of cardiomyocytes (hyperplasia), their size 
(hypertrophy), or a combination of the two. In order to distinguish these 
possibilities, I first examined the effect of the dal mutation on cardiomyocyte 
proliferation. I performed a bromodeoxyuridine (BrdU) incorporation assay on 
paraffin-embedded heart sections of E12.5 and E15.5 dal/dal and control 
embryos. BrdU is a thymidine analogue that incorporates into the DNA of 
proliferating cells and substitutes for thymidine during DNA replication. No 
differences were observed in the number of replicating cardiomyocytes based  
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Figure 3.5. Normal cellular proliferation in the endocardial cushions of 
E12.5 dal/dal embryonic hearts. Cardiac sections stained with BrdU from 
E12.5 control (A) and dal/dal (B) embryonic hearts were examined under 40X 
magnification. (C) There was no difference in the proportion of BrdU positive 
cells between control (38%) and dal/dal mutant (40%) endocardial cushion 
areas (p=0.467).  
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Figure 3.6. Cardiac valves were normally developed in dal/dal embryonic 
hearts. Histological examination of cardiac valve formation in E18.5 wild-type 
(A) and dal/dal (B) embryos showed that both the mitral (blue arrow) and 
tricuspid (purple arrow) valves were normally developed by late gestation. The 
thickened ventricular septum of dal/dal embryonic heart (B) is obvious.  
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Figure 3.7. The proliferation status of dal mutant cardiomyocytes was 
not altered. BrdU staining of E12.5 dal/dal and control embryonic hearts 
counterstained with hematoxylin. (A,B) E12.5 wild-type (A) and dal mutant (B) 
heart sections. The thickened ventricular wall of dal mutants is obvious. (C,D) 
High power (100X magnification) view of boxed areas in (A) and (B). The 
number of cells in the same field of view was lower in dal/dal hearts than 
controls (120 vs. 150 cells per field of view) and cells in dal mutants appeared 
to be more dispersed, with a greater spacing between nuclei than in control 
hearts. (E) Quantification of BrdU signals. There was no significant difference 
in the proportion of BrdU positive cells between dal mutant (30%) and control 
(28%) embryonic hearts (p=0.398). 
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on the proportion of BrdU positive cells out of the total number of cells within a 
given field of view (Figure 3.7): 30% (37/120) of cells were BrdU positive in 
dal/dal mutant hearts, while 28% (43/150) were positive in age-matched wild-
type hearts. In analyzing the BrdU-stained sections, it was noted that sections 
of dal/dal hearts consistently had fewer cells in a given field of view, and their 
nuclei seemed to be more dispersed, suggesting the cells might be larger 
(hypertrophic). This observation prompted me to isolate and culture 
cardiomyocytes from control and dal mutant embryonic hearts and compare 
their surface area. Cardiomyocytes from dal/dal embryos were significantly 
larger (~1.7-fold) than those isolated from wild-type embryos (p<0.0001, 
Figure 3.8). The mean cell surface area of dal/dal and control cardiomyocytes 
was 317 and 187 (arbitrary units), respectively. Based on the result of this 
experiment, I concluded that the thickened ventricles in dal/dal mutants reflect 
bigger cardiomyocytes (hypertrophic changes during development).  
Changes in the expression of the genes encoding the cardiac polypeptide 
hormones ANP and BNP are commonly used as a marker of cardiac 
hypertrophy. The expression level of these genes was therefore tested, with 
the expectation of their being elevated in the ventricles of dal mutant embryos. 
RNA was isolated from the hearts of 4 dal mutant and 4 wild-type E12.5 
embryos and used as template for qRT-PCR. While Anp and Bnp were 
consistently expressed at higher levels in dal embryonic hearts than in controls, 
the differences were not statistically significant (Figure 3.9). 
In order to examine the physiological consequences of cardiac hypertrophy, I 
analyzed calcium dynamics in dal embryonic hearts using pCAGGS-GCaMP  
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Figure 3.8. Cardiomyocytes from dal mutant embryos are hypertrophic. 
(A,B) Representative cardiomyocytes isolated from E15.5 dal/dal (A) and 
C3H/HeJ (wild-type control) (B) embryonic hearts. (C) The mean surface area 
of dal/dal cardiomyocytes (317 units) was almost 2-fold greater than that of 
wild-type cardiomyocytes (187 units) (* Student’s t-test: p<0.0001).  
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Figure 3.9. Expression of the hypertrophy markers Anp and Bnp appears 
to be elevated in some of dal mutant hearts. E12.5 dal mutant and control 
heart RNA was subjected to qRT-PCR for Anp and Bnp, which are commonly 
used markers of cardiac hypertrophy.  Although the differences were not 
statistically significant (0.2≤p<0.5), Anp and Bnp were consistently elevated in 
dal mutant hearts. 
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transgenic mice. The GCaMP transgene consists of the α-myosin heavy chain 
(MHC) promoter, enhanced green fluorescent protein (eGFP), calmodulin and 
RSET poly-His peptide (Tallini et al., 2006) (Figure 3.10). When calcium binds 
to calmodulin within the transgenic protein product during excitation-
contraction coupling (E-C coupling), eGFP undergoes a conformational 
change and emits green fluorescent light. The intensity of the GFP signal is 
therefore an indicator of calcium cycling. This system enables one to visualize 
molecular calcium information for a beating heart.  
While dal/+ embryonic hearts exhibited normal, synchronous calcium 
transients in a constant interval, 3 out of 7 (43%) dal/dal embryos showed 
features of abnormal calcium transients that included abnormal ectopic 
depolarizations during the repolarization period (EADs) and significant interval 
irregularities (Figure 3.11). This suggests that dal neonates might be 
susceptible to developing fatal cardiac arrhythmias during postnatal maturation. 
The hearts of imaged embryos were subsequently sectioned to determine 
whether ventricular thickness was correlated with calcium handling defects. 
The ventricles of hearts from dal/+ embryos and dal/dal embryos that had 
normal calcium transients were normal, while dal/dal embryos with altered 
calcium transients had thickened ventricular walls and septal defects (Figure 
3.11). Western blot analysis for SERCA2, one of the major intracellular 
calcium handling proteins, showed no significant difference in expression level 
between control and dal mutant hearts (Figure 3.12).  
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Figure 3.10. The structure of the in-vivo calcium sensor encoded by the 
pCAGGS-GCaMP transgene. When calcium (orange dots) binds calmodulin, 
a conformational change causes eGFP to fluoresce. A high resolution camera 
is used to detect the signal, which is translated as molecular calcium signals.  
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Figure 3.11. Abnormal calcium signaling is correlated with thickened 
ventricles in dal/dal mutant hearts. The hearts of Tg.pCAGGS; dal/dal and 
Tg.pCAGGS; dal/+ embryos were imaged to record GFP fluorescence that 
reflects calcium transients. (A, B) Normal calcium transients (A) and cardiac 
structure (B) in E12.5 dal/+ embryonic heart. (C-F) Altered calcium transients 
and corresponding thickened ventricles in E12.5 dal/dal embryonic hearts. 
Early afterdepolarization (EAD) (C) was observed in a dal/dal embryo with a 
prominent ventricular septum (red arrow in D). Irregular rhythm of calcium 
transients (E) was recorded from a dal/dal heart with thickened ventricles (red 
arrow in F) and ASD (blue arrow in F).  
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Figure 3.12. SERCA2a expression levels were not altered in E15.5 dal 
embryonic hearts. (A) No difference was observed upon Western blot 
analysis for SERCA2a between E15.5 control and dal embryonic hearts. (B) 
The mean relative intensity of SERCA2a signal, normalized to GAPDH loading 
control, showed no difference between controls and dal mutants (Student’s t-
test p=0.5629). 
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Identification of the dal gene 
Identifying the gene mutated in dal mutant mice was the next logical step in 
understanding the mechanism underlying abnormal cardiomyocyte 
hypertrophy in dal embryonic hearts. Harris et al. (Harris, 2003) had mapped 
the dal mutation to a 9.9 Mb region between D7Mit294 and D7Mit247. This 
interval contains approximately 250 genes. In order to refine the candidate 
interval to a small enough region for mutation analysis, an interspecific 
backcross (BC) population was established by breeding male and female dal/+ 
F1 (CBA/J-dal/dal x CAST/EiJ) mice to dal/dal mice (Figure 3.13). Some non-
recombinant agouti (dal/+) BC mice were also mated to dal/dal mutants to 
generate additional recombinant animals when the breeding performance of 
F1 animals declined. The genotype of BC mice at the dal locus was inferred by 
coat color (agouti vs. dark). A total of 944 BC mice were produced, among 
which 397 mice were dal and 547 were agouti. It is worth noting that 13/547 
agouti BC mice were homozygous for dal mutant strain alleles across the 
candidate interval. These 13 agouti BC mice were thus genotypically dal/dal 
but phenotypically agouti, indicating incomplete penetrance of the 
pigmentation phenotype. Penetrance of pigmentation phenotype was 
estimated to be 96.8% (=397/397+13) in this cross. In a BC, equal numbers of 
dal/dal and dal/+ progeny are expected. Since 534 dal/+ progeny were 
observed but only 410 dal/dal (by genotype across the candidate interval), this 
indicates reduced viability in this cross as well, with 124 (23%) of the expected 
dal/dal pups “missing” by 14-21 days of age. 
Genotyping 944 BC mice with the flanking markers D7mit114 and D7mit228,  
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Figure 3.13. Structure of the backcross pedigree used to map the dal 
mutation. A homozygous CBA/J-dal/dal male was outcrossed to CAST/EiJ 
females to produce F1 progeny. Male and female F1s were backcrossed to 
CBA/J- or C3.CB-dal/dal mice to generate a backcross population of dal/+ and 
dal/dal offspring. 
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Figure 3.14. Recombination mapping of the dal mutation. Backcross mice 
with recombination breakpoints (illustrated by change from a white box to a 
black box along the horizontal axis) within the candidate interval refined the 
dal locus to a 1Mb interval between the markers D7Mit79 and D7Mit78. 
Markers are given across the top in the order in which they lie (proximal-to-
distal) on chromosome 7. The number on the left (under “n”) indicates how 
many backcross animals showed the recombination event represented to the 
right. The genotype of all BC animals was consistent with their phenotype 
(homozygous CBA when dal, heterozygous when agouti) at D7Mit269 and 
D7Mit225, indicated by the gray box. 
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which defined a 19.7 Mb candidate interval, identified 102 BC mice with 
recombination events between these markers. These recombinant animals 
were then genotyped for 11 polymorphic microsatellite markers that span the 
interval to identify the position of recombination breakpoints, to refine the 
candidate interval (Figure 3.14). The dal locus was mapped to a 1.0 Mb region 
flanked by D7mit79 and D7mit78 that contains 11 annotated genes (Kctd15, 
Chst8, Pepd, Cebpg, Cebpa, Slc7a10, Lrp3, Gpatch1, Rhpn2, Riken clone 
C28005212 and Ccdc123) (Figure 3.15). 
Primers were designed to amplify the cDNA of each gene from dal/dal 
embryonic heart RNA. The sequence of PCR products for Pepd, Kctd15, 
Cebpg, Slc7a10, Gpatch1, Rhpn2, and Riken clone C28005212 were 
compared to the normal C57BL/6J sequence in the Ensembl database 
(http://www.ensembl.org/index.html). The only change identified was a 4 base-
pair deletion in exon 14 of Pepd (Figure 3.16A). This difference was confirmed 
by amplifying and sequencing the same region from an adult dal/dal testis 
RNA sample as well as amplifying and sequencing the corresponding region 
from CBA/J-+/+ and CBA/J-dal/dal genomic DNA. To further confirm that this 
was the mutation, primers were designed to amplify a 109 bp product 
spanning this interval that would allow the wild-type and dal mutant products 
(109 and 105 bp in size, respectively) to be resolved on a 5% NuSieve gel 
(Figure 3.16B). Genomic DNA of CBA/J-+/+,CBA/J-dal/+ and CBA/J-dal/dal 
was amplified and examined. CBA/J-dal/dal samples were homozygous for the 
smaller product, wild-type (CBA/J-+/+) DNA produced a single larger band and 
obligate CBA/J-dal/+ samples had three bands (wild-type, dal and non-specific 
band) (Figure 3.16B). 
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Figure 3.15. The dal candidate interval. Recombination mapping refined the 
map position of the dal locus to the 1 Mb interval between D7mit79 and 
D7mit78, which contains the 11 annotated genes illustrated.  
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Figure 3.16. The dal mutation is a 4 bp deletion in the Pepd gene.           
(A) Pepd gene sequence comparison of Ensembl genome browser data, 
CBA/J (the strain of origin of the dal mutation) and dal/dal genomic DNA. A 4-
bp deletion (ACTG) was detected in genomic DNA (and RNA from embryonic 
heart and adult testis) of dal mutant animals. (B) PCR analysis showing a 4 bp 
difference in the size of PCR products between CBA/J (109 bp) and dal/dal 
(105 bp) genomic DNA. Note that there are three bands for dal/+ samples. 
The lower two alleles represent wild-type and dal alleles, while the uppermost 
band is a non-specific band that was only observed in heterozygotes.  
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Pepd encodes the enzyme prolidase, which is a metalloproteinase that 
metabolizes imidodipeptides containing a carboxy-terminal proline or 
hydroxyproline residue (such as those found on collagen degradation products 
and in dietary proteins) (Figure 3.17). This enzyme is a rate-limiting factor in 
collagen turnover and plays an primary role in recycling proline, which is 
required for collagen biosynthesis and cell growth (Lupi et al., 2008). Prolidase 
is highly conserved between vertebrate species. 
Amino acid sequence alignments with ClustalW2 
(http://www.ebi.ac.uk/Tools/clustalw2) demonstrated that mouse and human 
prolidase are 89% identical at the amino acid level, while mouse and zebrafish 
are 54% identical (Figure 3.18). The Ensembl database identifies only one 
Pepd ortholog in zebrafish. Bioinformatic analysis (http://elm.eu.org) predicted 
that mouse prolidase has a putative cortactin-interacting motif (VPRLPDSYAT). 
Cortactin is an actin binding protein and a target of the Src tyrosine kinase (a 
downstream transducer of the integrin signaling pathway). Two transcripts 
have been identified for mouse Pepd. One of the resulting PEPD protein 
isoforms (ENSMUSP00000075683) was predicted to contain a mitochondrial 
localization signal in its first 37 amino acids. Wild-type Pepd encodes a 493 
amino acid protein, while the predicted dal mutant PEPD protein would have 
455 amino acids. The 4 bp deletion identified in the Pepd gene in dal mice is 
expected to cause a frame shift after amino acid 410, with a novel 45 amino 
acids preceding a premature stop codon. A BLAST search for the novel 
portion of the dal mutant PEPD product (http://blast.ncbi.nlm.nih.gov/Blast) 
failed to detect any conserved domains. 
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Figure 3.17. The role of prolidase in metabolism of collagen. The 
imidodipeptide targets of prolidase originate from intracellular degradation of 
procollagen, collagen, and other proline or hydroxyproline-containing peptides, 
including dietary proteins. Prolidase catalyzes the final step of their 
degradation into free amino acids in the cytoplasm. The primary biological 
function of prolidase in mammals is in the metabolism of collagen degradation 
products (imidodipeptides) and the recycling of proline from any amino acid 
containing proline-residues for collagen resynthesis. Imidodipeptides play 
important roles in collagen synthesis and degradation. In particular, 
imidodipeptides stimulate intracellular collagen degradation. 
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Mouse_PEPD_t1       -MASTVRPSFSLGNETLKVPLALFALNRQRLCERLRKNGAVQAASAVVLQGGEEMQRYCT 59 
Mouse_PEPD_t2       -VGSVVGPSFSLGNETLKVPLALFALNRQRLCERLRKNGAVQAASAVVLQGGEEMQRYCT 59 
dal_PEPD            -MASTVRPSFSLGNETLKVPLALFALNRQRLCERLRKNGAVQAASAVVLQGGEEMQRYCT 59 
Human_PEPD          -MAAATGPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCT 59 
Zebrafish_PEPD      MCVFNRKAVYWLGNDTLRVSAALFALNRERLCVGLKALPDLQAGSVVVLQGGEQKQRYCT 60 
                           . : ***:**:*. *******:***  *:    :**.* *******: ***** 
 
Mouse_PEPD_t1       DTSIIFRQESFFHWAFGVVESGCYGVIDVDTGKSTLFVPRLPDSYATWMGKIHSKEYFKE 119 
Mouse_PEPD_t2       DTSIIFRQESFFHWAFGVVESGCYGVIDVDTGKSTLFVPRLPDSYATWMGKIHSKEYFKE 119 
dal_PEPD            DTSIIFRQESFFHWAFGVVESGCYGVIDVDTGKSTLFVPRLPDSYATWMGKIHSKEYFKE 119 
Human_PEPD          DTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKE 119 
Zebrafish_PEPD      DTDETFRQDLFIHFCIIVTNCACEVACMLLQLKTELIVLLYPLSTVATLGELFPSPSLSQ 120 
                    **.  ***: *:*:.: *.: .*  .  :   *: *:*   * * .: :*::...  :.: 
 
Mouse_PEPD_t1       KYAVDDVQYTDEIASVLTSRNPSVLLTLRGVNTDSGSVCREASFEGISKFNVNNTILHPE 179 
Mouse_PEPD_t2       KYAVDDVQYTDEIASVLTSRNPSVLLTLRGVNTDSGSVCREASFEGISKFNVNNTILHPE 179 
dal_PEPD            KYAVDDVQYTDEIASVLTSRNPSVLLTLRGVNTDSGSVCREASFEGISKFNVNNTILHPE 179 
Human_PEPD          KYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPE 179 
Zebrafish_PEPD      RFIDENSDFDIMIADVLAKMKPSVLLTLRGLNTDSGSTCREASFEGISRFEVNNSLLHPV 180 
                    ::  :: ::   **.**:. :*********:******.******:***:*:***::***  
 
Mouse_PEPD_t1       IVE--CRVFKTDMELEVLRYTNRISSEAHR-EVMKAVKVGMKEYEMESLFQHYCYSRGGM 236 
Mouse_PEPD_t2       IVE--CRVFKTDMELEVLRYTNRISSEAHR-EVMKAVKVGMKEYEMESLFQHYCYSRGGM 236 
dal_PEPD            IVE--CRVFKTDMELEVLRYTNRISSEAHR-EVMKAVKVGMKEYEMESLFQHYCYSRGGM 236 
Human_PEPD          IVE--CRVFKTDMELEVLRYTNKISSEAHR-EVMKAVKVGMKEYELESLFEHYCYSRGGM 236 
Zebrafish_PEPD      IVEWICRLAQTFVLCASARIEHFYSGKKRKTLVMRRVKPGLKEYEMESLFQHYCYSRGGM 240 
                    ***  **: :* :     *  :  *.: ::  **: ** *:****:****:********* 
 
Mouse_PEPD_t1       RHTSYTCICCSGENAAVLHYGHAGAPNDRTIKDGDI--CLFDMGGEYYCFASDITCS--- 291 
Mouse_PEPD_t2       RHTSYTCICCSGENAAVLHYGHAGAPNDRTIKDGDI--CLFDMGGEYYCFASDITCS--- 291 
dal_PEPD            RHTSYTCICCSGENAAVLHYGHAGAPNDRTIKDGDI--CLFDMGGEYYCFASDITCS--- 291 
Human_PEPD          RHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDM--CLFDMGGEYYCFASDITCS--- 291 
Zebrafish_PEPD      RHTSYTCICGSGNNSSILHYGHAGAPNDKTIQDGDMWSCLFDEIMLSLCYLVDLCCSVFV 300 
                    **:****** **:*:::***********:**::**:  ****      *:  *: **    
 
Mouse_PEPD_t1       FPANGKFTEDQKAIYEAVLRSCRTVMSTMKPGVWWPDMHRLADRIHLEELARIGLLSGSV 351 
Mouse_PEPD_t2       FPANGKFTEDQKAIYEAVLRSCRTVMSTMKPGVWWPDMHRLADRIHLEELARIGLLSGSV 351 
dal_PEPD            FPANGKFTEDQKAIYEAVLRSCRTVMSTMKPGVWWPDMHRLADRIHLEELARIGLLSGSV 351 
Human_PEPD          FPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSV 351 
Zebrafish_PEPD      SPRSPTLFSHFRTLLVRFLMSQYDFMAALNSGVKWTDMHRLADRVHLEELLKIGILHGDV 360 
                     * . .:  . :::   .* *   .*.:::.** *.********:***** ::*:* *.* 
 
Mouse_PEPD_t1       DAMLQVHLGAVFMPHGLGHFLGLDVHDVGGYPEGVERIDEPGLRSLRTARHLEPGMVLTV 411 
Mouse_PEPD_t2       DAMLQVHLGAVFMPHGLGHFLGLDVHDVGGYPEGVERIDEPGLRSLRTARHLEPGMVLTV 411 
dal_PEPD            DAMLQVHLGAVFMPHGLGHFLGLDVHDVGGYPEGVERIDEPGLRSLRTARHLEPGMVLWS 411 
Human_PEPD          DAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTV 411 
Zebrafish_PEPD      EEMLKVHLGSVFMPHGLGHLLGIDVHDVGGYPEGVERVDEPGLKSLRMGRVVQERMVLTV 420 
                    : *::.***:*********:**:**************:*****:*** .* ::  ***   
 
Mouse_PEPD_t1       EPGIYFIDHLLDQALADPAQACFFNQEVLQRFRNFGGVRIEEDVVVTDSGMELLTCVPRT 471 
Mouse_PEPD_t2       EPGIYFIDHLLDQALADPAQACFFNQEVLQRFRNFGGVRIEEDVVVTDSGMELLTCVPRT 471 
dal_PEPD            QASTSLTTSWTRPWQTRPKPASLTKRSCSASATSVG-------------------CGSRK 452 
Human_PEPD          EPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRT 471 
Zebrafish_PEPD      EPGIYFINHLLDKALASPAQCGFINTAVLTRFRGFGGVRTHTYIAVTADGVELLTCVPRT 480 
                    :..  :         : *  . : :        ..*                   * .*. 
 
Mouse_PEPD_t1       VEEIEACMAGCD-KASVPFSGQK- 493 
Mouse_PEPD_t2       VEEIEACMAGCD-KASVPFSGQK- 493 
dal_PEPD            MLS--------------------- 455 
Human_PEPD          VEEIEACMAGCD-KAFTPFSGPK- 493 
Zebrafish_PEPD      VEEIEAFMAEETSKPFSPISSQKL 504 
                    : .                      
Figure 3.18. Comparison of mouse, human and zebrafish PEPD amino 
acid sequences. Amino acid sequence alignment showed that PEPD is highly 
conserved across species.  
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Premature stop codons often result in reduced mRNA expression level of a 
gene through a mechanism called nonsense-mediated decay (Chang et al., 
2007; Isshiki et al., 2001). Pepd RNA levels were quantified to investigate the 
effect of the dal mutation on Pepd expression. A significant (~42%) reduction 
in Pepd expression was observed in E15.5 dal/dal heart RNA compared to 
age-matched wild-type control hearts (p=0.0066; Figure 3.19). This indicates 
that the dal mutation is most likely hypomorphic, resulting in at least a partial 
loss of PEPD function. Interestingly, there was greater variation in Pepd levels 
in dal mutant embryos: relative quantification (RQ) values of Pepd expression 
in 3 C3H control embryos were 1, 0.86 and 0.922, for a mean value of 0.9273, 
while those in 4 dal/dal embryos were 0.426, 0.72, 0.45 and 0.568, for a mean 
value of 0.5410. 
A conserved function for PEPD in zebrafish 
Cardiac phenotypes have not been reported in humans with prolidase 
deficiency. To test whether the phenotypes of dal mutant mice reflect 
evolutionarily conserved roles of PEPD and confirm that the dal mutation 
causes a loss of PEPD function, I used an antisense morpholino approach to 
determine the effect of knocking down Pepd expression on the phenotype of 
zebrafish embryos. Mouse Pepd is composed of 15 exons and the 4 bp 
(ACTG) mutation in dal mice is located in exon 14. Zebrafish Pepd consists of 
21 exons and the same sequence (ACTG) that is mutated in dal mice is 
conserved (located in exon 20) in zebrafish Pepd. The goal of the study 
described in this section was to generate a loss-of-function mutation in  
110 
 
 
 
 
 
 
 
 
 
Figure 3.19. The dal mutation results in reduced Pepd RNA levels. 
Relative quantitative RT-PCR was used to determine whether the dal mutation 
affects Pepd expression. As compared to control embryonic hearts, Pepd 
mRNA levels were reduced ~42% in dal/dal E15.5 hearts. The mean RQ value 
was significantly different between the two groups (* Student’s t-test, p=0.0066) 
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zebrafish Pepd that would be similar in nature to the dal mutation (introduce a 
premature stop codon and a frame shift at approximately the same location). 
Pepd_MO was designed against the splice acceptor site of exon 20. This was 
predicted to cause either insertion of intron 19 into or deletion of exon 20 from 
the spliced mRNA product (Figure 3.20). This strategy was preferred over 
translational blocking because the targeted intronic insertion or exon deletion 
could be easily screened for by RT-PCR, while there is no antibody available 
against PEPD to use in monitoring the success and efficiency of translation 
blocking. Pepd_MO injection successfully modified splicing events, resulting in 
larger RT-PCR products in which intron 19 was inserted into the Pepd 
transcript (Figure 3.21). Insertion of intron 19 was confirmed by sequencing 
the RT-PCR products (data not shown) and is expected to introduce a frame 
shift and premature stop codon (Figure 3.20). Control_MO did not change 
Pepd transcription (Figure 3.21).  
Zebrafish embryos injected with  Pepd_MO or Control_MO on day 0 dpf were 
collected on 5 dpf for phenotype analyses as this is the time point at which 
cardiogenesis is complete in zebrafish (Sprague et al., 2001). Gross 
examination revealed multiple developmental abnormalities in PEPD_MO-
injected embryos that were not present in embryos injected with control_MO. 
These abnormalities included defective pigmentation, small body and eye size, 
and a swollen pericardial sac (Figures 3.22 and 3.23). Defective pigmentation 
and small eyes were observed in 67.6% of embryos with small body size. 
Among those with defective pigmentation, the majority (71%) were hyper-
pigmented (darker pigment patches on dorsal and ventral body surface), while 
pigment cells were disorganized in the rest (29%) (Table 3.6).   
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Figure 3.20. Predicted outcomes of zebrafish morpholino strategy. (A) 
Wild-type mouse PEPD consists of 493 amino acids, while the 4-bp deletion 
present in exon 14 (indicated by blue bar above sequence) of Pepd gene in 
dal mutant mice results in a frame shift (indicated by purple sequence) starting 
at 410th amino acid and a premature stop codon, which produces a truncated 
PEPD protein. (B) Morpholino antisense oligonucleotides targeting the 
acceptor donor site of exon 20 in zebrafish Pepd gene could result either in 
deletion of exon 20 or insertion of intron 19, either of which will successfully 
introduce a frame shift and premature stop codon into the RNA exon 20. 
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Figure 3.21. Antisense morpholino (MO) oligonucleotides knockdown of 
zebrafish Pepd. (A) Pepd_MO specifically targeted the splice acceptor 
sequence of exon 20 of the zebrafish Pepd gene. (B) Injection of Pepd_MO 
into zebrafish embryos was predicted to result in either deletion of exon 20 or 
insertion of intron 19. The wild-type mRNA is 502 bp. Deletion of exon 20 
would shorten this to 294 bp, while insertion of intron 19 would add 241 bp to 
the transcript and result in a 743 bp RT-PCR product using primers indicated 
(F and R). (C) RT-PCR using RNA extracted from embryos injected with 
Control_MO or Pepd_MO was performed to confirm successful modification of 
Pepd pre-mRNA. A 502 bp RT-PCR product was observed using Control_MO 
RNA, while a 743 bp product was produced from Pepd_MO RNA. This 
indicates that Pepd_MO successfully modified the splicing of pre-mRNA 
sequences by inserting intron 19. The reduced intensity of RT-PCR product 
from Pepd_MO in comparison to that of Control_MO suggests nonsense-
mediated decay of the disrupted transcript.  
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Figure 3.22. Pepd_MO-treated zebrafish showed hyperpigmentation and 
small body size. (A,B) Stereomicroscopic views of Control_MO (A) and 
Pepd_MO (B) injected embryos. Normal body size and pigment distribution 
were observed in Control_MO injected embryos (A), while Pepd_MO –injected 
embryos often exhibited a small body and eye size (B). Note that pigment is 
clumped on the surface of chest area and at the tail of the Pepd_MO-injected 
embryo (B). (C,D) Magnified view of chest area in A and B. Normally 
distributed pigment was evenly spaced and aligned along the body surface of 
Control_MO injected zebrafish (C), while Pepd_MO-treated embryos had 
patches of hyperpigmentation and/or a disorganized distribution of pigment 
cells. 
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Figure 3.23. A swollen pericardial sac was observed in some Pepd_MO-
injected zebrafish. Stereomicroscopic views of Control_MO (A) and 
Pepd_MO (B) injected embryos (B). PEPD_MO treated embryos often 
displayed a swollen pericardial sac (black arrow) at 5 days post fertilization 
(dpf). 
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Table 3.6.  Morpholino knockdown of Pepd in zebrafish embryos causes 
multiple developmental defects 
 Control_MO 
injected embryos 
(n=63) 
Pepd_MO   
injected embryos  
(n=97) 
 n  n (%) 
Small body size 0 63 (65) 
Small eye size 0 63 (65) 
Unhatched eggs 0 15 (15) 
Swollen pericardial sac 0 47 (48) 
Defective pigmentation 0 63 (65) 
 -Hyperpigmentation 0 45 (46) 
 -Disorganized pigmentation 0 18 (19) 
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A swollen pericardial sac was observed in 48% of PEPD_MO-injected 
embryos. The dysmorphic appearance of Pepd_MO-injected embryos altered 
the position of landmark structures (relative to control embryos), making 
histological analysis difficult. Therefore, in order to examine the effect of 
Pepd_MO on heart development, cardiac MLC-GFP transgenic zebrafish were 
injected and examined by confocal microscopy. Relative to the hearts of 
control_MO-injected embryos, the Pepd_MO-injected fish had multiple 
developmental cardiac defects including homogeneously thickened ventricular 
free walls with less trabeculation, a smaller ventricular chamber and a 
narrower atrioventricular annulus (Figures 3.24 and 3.25). The diameter of the 
ventricular outflow tract was not different, which indicates that disrupting PEPD 
affects normal myocardial development but not vasculogenesis.  
Linking Pepd to cardiac hypertrophy  
The studies described above demonstrate that loss of PEPD function 
underlies the cardiac and pigmentation defects observed in dal mutant mice 
and that PEPD has an evolutionarily conserved role in heart development and 
pigmentation. The next logical question was: what is the function of PEPD 
(prolidase) in cardiomyocyte development? Since prolidase has been 
implicated in collagen biosynthesis and recycling, I hypothesized that the dal 
mutation disrupts the extracellular collagen content, which in turn affects 
integrin signaling and organization of the cytoskeleton to trigger premature 
hypertrophic cardiomyocyte growth. Loss of prolidase would be predicted to 
alter ECM collagen content. Picrosirius red staining on cardiac sections of 2 
month-old controls and dal mutants showed that collagen in wild-type hearts 
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Figure 3.24. Thickened ventricular walls were observed in cardiac MLC-
GFP transgenic zebrafish injected with Pepd_MO. Confocal sections of 
Control_MO-injected (A-D) and Pepd_MO-injected (E-H) zebrafish embryonic 
hearts. Ventricular walls of Pepd_MO-injected embryos (E-H) were 
consistently thicker, with reduced ventricular trabeculation, than those of 
control embryos (A-D) throughout multiple serial images.  
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Figure 3.25. Developmental cardiac phenotypes observed in dal mutant 
mice were recapitulated by Pepd_MO knockdown in zebrafish embryos. 
The following features of cardiac anatomy were measured (as indicated on 
panel E): ventricular wall thickness (A), ventricular chamber dimension (B), AV 
annulus diameter (C), and ventricular outflow tract diameter (D). The 
ventricular myocardium (A) of Pepd_MO injected embryos was 
homogeneously thicker than that of Control_MO injected zebrafish (p<0.0001). 
The diameters of the internal ventricular chamber (B) and AV annulus (C) of 
Pepd_MO-injected zebrafish were much smaller than those of Control_MO 
injected zebrafish hearts (p<0.0001 and p=0.0003, respectively). The diameter 
of the ventricular outflow tract (D) was equivalent between the two groups 
(p=0.9618). 
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was regularly polymerized and well distributed, whereas there was a reduction 
in the total amount and extent of polymerization of collagen in dal/dal heart 
(Figure 3.26). The Picrosirius red staining method was not able to visualize 
collagen in embryonic heart sections.  
Collagen is the major ligand of integrin receptors (specifically α1β1, α2β1, 
α10β1, α11β1) which transmit extracellular information to subcellular 
cytoskeletal structures through signal transducers such as FAK (focal 
adhesion kinase), Src (cytoplasmic tyrosine kinase) and paxillin (adaptor 
protein of integrin-actin link complexes). Western analysis was performed to 
determine whether the level of integrin transducer proteins was altered in dal 
mutant embryonic hearts. Phospho-FAK, phospho-Src, total Src and paxillin 
were all significantly reduced (p<0.05) in E15.5 dal/dal hearts relative to 
controls (Figure 3.27).  
Altered integrin signaling would be expected to affect the structure and/or 
organization of actin filament structures to which integrin signaling is 
transmitted. Wild-type and dal mutant cardiomyocytes were stained with 
fluorescently-conjugated phalloidin, which specifically binds F-actin. Confocal 
microscopic examination of wild-type cardiomyocytes showed a linear and 
continuous alignment of actin filaments (Figure 3.28 A and C). In contrast, 
dal/dal embryonic cardiomyocytes had an unusual pattern of F-actin 
distribution and organization, with an interrupted alignment of the sarcomeric 
actin banding pattern as well as a disorganized arrangement of actin filaments 
(Figure 3.28 B and D). Western blot analysis showed a significant reduction of 
filamentous actin (F-Actin) in E15.5 dal hearts relative to controls (Figure 3.29). 
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Figure 3.26. Extracellular collagen is reduced in dal mutant hearts. The 
content and distribution of extracellular collagen was examined by Picrosirius 
red staining of paraffin-embedded cardiac sections of 2 month-old mice. (A) 
Red-stained collagen was normally polymerized and distributed throughout the 
myocardium of control mice. (B) In dal/dal hearts, there was a strong reduction 
in the amount of collagen and it did not form long polymers. 
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Figure 3.27. Integrin signaling was altered in dal/dal embryonic hearts.  
(A) The protein expression level of total Src, phospho-Src, phospho-FAK and 
Paxillin was reduced in hearts of E15.5 dal embryos compared to controls. 
Total FAK was not changed. (B) The signal intensity of each protein was 
normalized against GAPDH. The mean relative intensity of total Src, phospho-
Src, phospho-FAK and Paxillin was significantly lower in dal mutant hearts 
than in control hearts (* Student’s t-test p-value: 0.001, 0.0026, 0.0088 and 
0.0002, respectively). No significant change was detected in the level of total 
FAK protein between controls and dal embryonic hearts (Student’s t-test 
p=0.4). 
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Figure 3.28. Actin cytoskeleton abnormalities in dal mutant embryonic 
cardiomyocytes. The actin cytoskeleton, which is the major sarcomeric 
structure of cardiomyocytes, was stained with fluorescently labeled Phalloidin 
and imaged by confocal microscopy. (A,C) A representative wild-type 
cardiomyocyte, showing linear stretches of normal actin filaments. (B,D) A 
representative dal/dal mutant cardiomyocyte, displaying an abnormal, 
interrupted banding pattern of actin filaments.  
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Figure 3.29. Actin was reduced in dal/dal embryonic hearts. (A) Western 
blot analysis revealed reduced levels of filamentous actin (F-Actin) in the 
hearts of E15.5 dal embryos compared to controls. (B)  The signal intensity of 
F-Actin signal was quantified and normalized against GAPDH. The mean 
relative intensity of F-Actin signal in dal mutant samples was significantly lower 
than that of controls (* Student’s t-test p=0.0092). 
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Discussion 
Hemodynamic overload chronically imposed to the heart is known as a major 
trigger of adult-onset cardiac hypertrophy in clinical cardiac diseases. It was 
quite surprising to discover cardiac hypertrophic changes in embryonic hearts, 
particularly because it is known that embryonic cardiac growth is mainly 
accomplished by hyperplasia, with hypertrophic changes in cardiomyocytes 
not normally starting until postnatal day 3 in mice (Oparil et al., 1984). The dal 
mutant mouse therefore represents a novel model for decoding the genetic 
and molecular mechanisms of myocardial hypertrophic changes, as well as 
the normal transition from proliferative to hypertrophic cardiomyocyte growth.  
Cardiac hypertrophy can be abnormally induced by numerous stimuli such as 
ECM proteins, growth factors, neurohormones, mechanical stress and 
cytokines. Cardiac ECM consists of structural proteins (collagen, elastin), 
adhesive proteins (fibronectin, laminin) and proteoglycans (Corda et al., 2000). 
Proliferating cardiac fibroblasts produce type I and III collagen as well as 
fibronectin. Cardiomyocytes synthesize type IV collagen and laminin (Klewer 
et al., 1998). Collagen as a ligand is sensed by integrin receptors to influence 
a downstream signaling pathway that connects the ECM to the sarcomeric 
contractile apparatus (Kempiak et al., 2005). There are 18 integrin α-subunits 
and 8 β-subunits. Cardiomyocytes express integrins α-1,3,5,6,7,9,10 and β-
1,3,5, to (theoretically) form 18 different heterodimers (Brancaccio et al., 2006; 
Lal et al., 2007). Different heterodimers bind to different types of collagen 
protein and are involved in distinct physiological functions.  
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My data suggest that the mechanism underlying developmental cardiac 
hypertrophy in dal mutant embryos involves the ECM-integrin-sarcomere axis. 
Since the actin cytoskeleton is a dynamic structure that changes its shape and 
organization in response to upstream signaling transduction (Fuller et al., 
1998), I propose a model in which alteration of the extracellular collagen 
matrix due to loss-of-function of PEPD in dal mutant embryonic hearts signals 
through integrin receptors and transducers to modify the subcellular 
cytoskeletal structure, leading to cardiomyocyte hypertrophy. This observation 
is consistent with the previous finding that abnormal cytoskeletal sarcomeric 
remodeling is the subcellular phenotype that underlies acquired hypertrophic 
cardiomyopathy (Kim et al., 2003). Ieda et al. recently reported that integrin 
signaling and ECM proteins are involved in embryonic myocardial 
development (Ieda et al., 2009). ECM proteins such as collagen and 
fibronectin secreted from cardiac fibroblasts collaboratively enhanced the 
proliferation of embryonic cardiomyocytes via β1 integrin signaling. 
Interestingly, the study showed that integrin β1 and fibronectin mRNA levels 
peak at mid-gestation and drastically subside over the remaining gestation 
period (Ieda et al., 2009). A question remains as to whether the reduced 
expression of these genes in late gestation is a prerequisite to providing an 
environment in which myocardial growth switches from hyperplasia to 
hypertrophy after birth.  
Does prolidase control extracellular matrix production from cardiac fibroblasts, 
regulating cardiomyocyte growth during the transition phase? Based on the 
finding that cardiomyocyte hypertrophy is manifested in dal mutant embryonic 
hearts, where the level of Pepd mRNA, integrin transducers and extracellular 
133 
 
collagen proteins is reduced, I hypothesize that prolidase may be a critical 
determinant of normal transition process that triggers hypertrophic changes. 
Further studies are needed to test whether integrin signaling and/or prolidase 
plays a crucial role in the normal postnatal hypertrophic transition process in 
an integrin-dependent manner. This could be accomplished by determining 
whether there is a significant reduction in the expression level of integrin 
and/or Pepd transducers in normal hearts over the period during which this 
transition takes place (postnatal day 1-5 in mice).  
Lipid microdomains play important roles in localizing Src and FAK for integrin-
dependent interaction with the ECM. Two major lipid microdomains include 
lipid rafts and caveolae (Galbiati et al., 2001). A study showed that Src is 
largely localized to cholesterol-enriched lipid raft domains (Liang et al., 2001). 
In dal mutant embryonic hearts, the extent of the change in the level of Src 
was more remarkable than that of FAK, while caveolin-1 levels were 
equivalent to controls (data not shown). The level of the lipid raft marker, 
flotillin, is reduced in adult dal/dal testis (Cota et al., 2008), but has not been 
examined in dal/dal embryonic hearts. Further studies to determine whether 
lipid rafts are disrupted in dal mutant embryonic hearts would provide useful 
information to test the hypothesis that Src kinase levels are significantly 
reduced due to loss of lipid rafts in addition to reduced ligand binding of 
extracellular collagen to integrin receptors.  
There was incomplete penetrance of cardiac phenotypes in dal mutant 
animals, with ~67.6% of mutant embryonic hearts being hypertrophic. 
Although it cannot be proven without histological analysis, it is tempting to 
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speculate that the hearts of the dal mutant embryos with higher Pepd 
expression might have had a normal cardiac structure while those with lower 
values might have had thickened ventricles and higher Anp expression. In 
other words, variation in Pepd expression among dal embryos could explain 
the incomplete penetrance of cardiac phenotypes. When Pepd expression falls 
below the threshold required for a normal cardiac development, cardiogenesis 
would be disrupted and result in abnormal production of extracellular collagen 
and altered integrin signaling in dal embryos. Further studies are warranted to 
correlate the expression of Pepd and Anp with ventricular thickness.  
Some dal embryos showed cardiac defects in addition to cardiac hypertrophy, 
including ASDs, VSDs and enlarged endocardial cushions. Many genetic 
mutations have been shown to cause septal defects in animal models and 
humans, and they are known to compromise normal growth and fusion of 
septum primum and septum secondum. An epithelial-to-mesenchymal 
transition (EMT) process takes place in the endocardial cushion, where 
endocardial cells are transformed into mesenchymal cells. These cells 
eventually give rise to cardiac valves and portions of AV septae. The ECM 
plays an important role in multiple cellular processes such as cell-to-cell 
communication, adhesion, migration and growth. Interaction between 
mesenchymal cells and ECM is known to regulate mesenchymal cell migration 
and expansion into endocardial cushions. Reduced collagen due to loss of 
prolidase in dal mutant embryonic hearts would be expected to attenuate the 
expansion of endocardial cushions, however, which is opposite to what was 
observed in some dal embryonic hearts. Further studies are needed to 
determine whether enlarged endocardial cushions in dal mutant embryonic 
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hearts result from increased number of cellular proliferation, larger cell size or 
cell migration defects.   
In humans, prolidase deficiency (PD) caused by mutations in PEPD has been 
reported as a rare autosomal recessive disorder associated with skin 
ulceration, developmental delay, imidodipeptiduria and skeletal deformities 
(Endo and Matsuda, 1991; Falik-Zaccai et al., 2009). Interestingly, no cardiac 
phenotypes have been reported in human PD patients, while skin ulcerations 
and skeletal deformities have not been observed in dal mice. This might be 
due to differences in the types or location of mutations in human PEPD which 
could have distinct effects on collagen production and metabolism, or may 
reflect genetic background effects and/or species differences. Cardiac defects 
and dark fur in dal mutants were incompletely penetrant, and cardiac defects 
often resulted in embryonic lethality in dal mutant embryos. By analogy, 
cardiac defects might not be present in all humans with PD and when they are, 
they may be lethal during fetal development. Loss-of-function of Pepd affected 
myocardial development, pigmentation and body size in zebrafish, indicating a 
conserved role for prolidase between zebrafish and mouse.  
Differences exist in human and mouse pigmentary systems. Pigment-type 
switching process, which results in transient expression of agouti, does not 
take place in human hairs. This might explain the absence of coat color 
phenotypes associated with human PD. Interestingly, premature aging of the 
skin due to photoaging not only induces the synthesis of collagenase, but also 
upregulates α-MSH, which signals through MC1R to promote eumelanin 
production (Kiss et al., 1995). α-MSH is known to attenuate the synthesis of 
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collagen production in human dermal fibroblasts (Bohm et al., 2004) and a 
microarray study revealed that melanocytes treated with agouti signal protein 
(ASP) upregulate genes involved in extracellular matrix-integrin receptor 
interactions and cell adhesion and migration (Le Pape et al., 2009). This 
suggests that there may be a close relationship between the expression level 
of ASP, extracellular matrix and integrin signaling. Since dal mutation acts 
downstream of agouti transcripts and upstream of Mc1r, it is possible that the 
effect of the dal mutation is to suppress ASP binding to the MC1R. Further 
studies are needed to test whether extracellular collagen is needed for ASP to 
reach melanocytes or promotes ASP binding to MC1R.  
Collagen proteins, which maintain tissue homeostasis and integrity, account 
for about 70~80 percentage of the skin (Stadelmann et al., 1998). The etiology 
of skin ulceration in human PD remains defined. Although collagen deprivation 
may be a contributing factor, a lack of collagen production does not 
necessarily result in skin ulceration. It is rather a combination of metabolic 
disorders, abnormal skin integrity, immune-mediated inflammatory response 
and susceptibility to infectious organisms. The pathogen-free environment of a 
laboratory animal facility as well as the fur on their skin may protect dal mutant 
mice from agents that can cause skin damage. It would be interesting to test 
whether loss of prolidase delays the wound healing time in dal mutant mice. 
This information would provide useful insights into understanding a different 
mechanism of phenotypic expression between humans and mice.  
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Summary 
This chapter identifies the mouse dark-like (dal) pigmentation mutant as a 
novel model for studying the genetic and molecular basis of developmental 
cardiomyocyte hypertrophy and for understanding the normal transition 
process of cardiomyocyte growth. I identified a mutation in Pepd that underlies 
these defects in dal mutant mice and used a reverse genetic approach in 
zebrafish to confirm that loss-of-function of Pepd has conserved effects on 
cardiogenesis, pigmentation and growth. Pepd encodes an enzyme called 
prolidase, which is integral to normal collagen biosynthesis and recycling. This 
work provides novel insights into the role of Pepd in developmental cardiac 
hypertrophy via remodeling of extracellular collagen, integrin signaling and 
actin organization in dal mutant embryonic hearts.  
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CHAPTER 4 
SUMMARY AND CONCLUSIONS 
Cardiovascular disease is the leading cause of death in the United States 
(Lloyd-Jones et al., 2009). In particular, cardiac hypertrophy and arrhythmias 
are major risk factors for sudden cardiac death (Wachtell et al., 2008). These 
diseases are genetically and phenotypically heterogeneous, which 
complicates studies to elucidate the genetic and molecular causes. Animal 
models therefore provide valuable opportunities to study the mechanisms 
underlying human cardiac disorders and offer critical insights that will be useful 
for developing both diagnostic tests and therapeutic treatments for both 
human and animal heart diseases. In the work presented here, a 
comprehensive investigation was performed to unravel the genetic and 
molecular mechanisms behind arrhythmias and cardiac hypertrophy in dogs 
and mice.  
Inherited ventricular arrhythmias in German shepherd dogs 
Young German shepherd dogs (GSDs) are predisposed to inherited 
ventricular arrhythmias and sudden cardiac death. Peak affectedness occurs 
between 20 and 28 weeks of age after birth. The cardiac autonomic system 
does not develop or mature  properly as there is reduced sympathetic 
innervation of the left anterior apical region (Dae et al., 1997). Such 
sympathetic denervation has been proposed to be one of the predispositions 
for familial ventricular arrhythmias in humans (Vincent, 1998). Cardiac 
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electrophysiology in GSDs showed evidence of abnormal calcium transients 
such as EADs and DADs (Steinberg et al., 2002), which are also known to be 
a prerequisite substrate for developing fatal ventricular arrhythmias (Michael et 
al., 2009). Phenotypic and etiologic similarity between GSDs and human 
patients with familial ventricular arrhythmias suggests that identifying the 
genetic and molecular mechanisms underlying arrhythmogenicity in GSDs will 
benefit human health. It will also allow for the development of genetic tests 
and therapies to benefit the GSD population.  
A genome-wide linkage analysis was performed to detect genomic region(s) 
linked to arrhythmias in GSDs. However, both parametric and non-parametric 
linkage analyses failed to discover any regions of strong linkage. As discussed 
in Chapter 2, a genome-wide association study of severely affected and 
unaffected dogs using SNP chips may be more successful in identifying a 
haplotype block that segregates with ventricular arrhythmias in GSDs, 
although pinpointing the specific genes/mutations may still be difficult since 
related affected breeds are not obviously available. My work identifying a 
significant inverse correlation between ATP2A2/SERCA2 levels and 
affectedness in GSDs may assist in the identification of candidate genes within 
a haplotype block, however, as this implicates at least one gene that acts 
upstream of ATP2A2 transcription. The genes that underlie susceptibility to 
ventricular arrhythmias in GSDS will be candidates for modifiers of human 
familial ventricular arrhythmias, and their identity will help us understand the 
molecular mechanism(s) that underlie this disease.  
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Developmental cardiac hypertrophy in dark-like mice 
Pleiotropic roles of genes that regulate pigment-switching pathway have 
demonstrated that coat color phenotype can be a visible marker of perturbed 
homeostasis in systemic organ development and maturation (Cota et al., 2006; 
Gunn et al., 2001; He et al., 2003). The recessive dark-like (dal) mutation 
causes a darkened coat color, gonad abnormalities, and small body size, 
(Cota et al., 2008; Harris, 2003). Here, I report that the dal mutation also 
causes heart defects, including markedly thickened cardiac ventricular walls 
and septa and atrial and ventricular septal defects. These defects would 
account for the reduced viability of dal embryos that was previously observed, 
and led me to hypothesize that the gene mutated in dal mice plays a pivotal 
role in myocardial development. Analysis of the proliferation status and size of 
dal mutant cardiomyocytes confirmed hypertrophy as the cause of the 
thickened myocardium. In fact, cardiomyocytes from dal mutant embryonic 
hearts were almost twice as large as those from control embryos. In addition, 
histological analysis of 3 month old dal hearts showed myocardial disarray, 
which is a typical sign of cardiac hypertrophy in humans and cats (Ly et al., 
2005). Embryonic cardiac hypertrophy was shown to have physiological and 
functional consequences as that the hearts of dal/dal embryos displayed 
abnormal calcium cycling with early afterdepolarization (EAD) and irregular 
intervals in calcium cycling. 
While many genetic mutations implicated in septal defects have been 
identified (Srivastava and Olson, 2000), little is known about the genes that 
can cause developmental cardiac hypertrophy or that regulate the normal 
141 
 
transition from proliferative to hypertrophic cardiomyocyte growth. To the best 
of my knowledge, dal mutants represent the first mouse model with the unique 
phenotype of premature (developmental) cardiac hypertrophy. Identification of 
the dal gene as Pepd (peptidase D), which encodes the enzyme prolidase, 
implicates collagen metabolism and integrin signaling in developmental 
cardiomyocyte hypertrophy. Reduced Pepd levels in dal mutant mice 
suggested that the dal mutation is hypomorphic (partial loss-of-function), and 
morpholino knock-down of Pepd in zebrafish confirmed that reduced levels of 
normal Pepd during embryonic development results in pigmentation and 
cardiac defects and small body size. I demonstrated that collagen was 
reduced in the hearts of dal mutant mice, as would be expected if prolidase 
activity was compromised. As predicted (since collagen signals through 
integrin receptors), expression of the major integrin transducers (FAK, Paxillin, 
Src) was reduced in the hearts of dal mutant embryos. This was associated 
with a disrupted pattern of collagen polymerization in dal mutant 
cardiomyocytes.  
Based on my results, I propose the following model for cardiomyocyte growth 
(Figure 4.1): during normal cardiac development, prolidase plays a critical role 
in the proper metabolism of collagen, which in turn functions as a signaling 
molecule that regulates normal myocardial growth and intracellular 
cytoskeletal organization through integrin pathways. Collagen and integrin 
expression is maintained during active cardiogenesis, gradually declines over 
the late gestation, and shortly after birth undergoes a drastic reduction. That 
causes hyperplastic growth to be terminated and hypertrophic growth to be 
activated. In dal mutant embryos, however, prolidase levels are always  
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Figure 4.1. Proposed model for the development of cardiac hypertrophy 
in dal mutant hearts. (A) Integrin α/β heterodimeric receptors sense and bind 
extracellular matrix proteins and transmit the extracellular information to the 
subcellular cytoskeleton via integrin transducers. (B) Loss of prolidase function 
in dal mutant mice alters the content and distribution of extracellular collagen. 
Integrin receptors sense the modified ligand binding of collagen, which is 
transmitted through integrin transducers (FAK, Src, Paxillin) to sarcomeres. 
The cytoskeletal sarcomere accordingly changes its shape and organization in 
response to the upstream signaling stimuli. Remodeling processes in the 
ECM-Integrin-Sarcomere axis thus result in cardiomyocyte hypertrophy during 
embryonic development in dal mutant mice.  
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reduced. This reduced prolidase activity would result in a series of alterations 
in a developing heart. In dal embryonic heats, reduced extracellular collagen 
levels would act as a signal that would prematurely change integrin signaling. 
Integrin receptors, so called mechanosensors on the cell surface, would 
recognize the changes in ECM composition and signaling to downstream 
transducers would be altered. The cytoskeletal sarcomere would change its 
shape and organization accordingly, causing cardiomyocytes to become larger. 
This reduced level of extracellular collagen and integrin that is predicted to 
normally take place in early postnatal period would occur early during cardiac 
development in dal mutant embryos to prematurely activate cardiomyocyte 
hypertrophy. This, however, might occur independent of terminating 
cardiomyocyte proliferation since normal myocardial proliferation was 
observed in dal embryos. This implies that the level or activity of prolidase is 
one of major determinants that turns on the transitional switching process of 
cardiomyocyte growth. This provides a series of testable hypotheses. For 
example: does Pepd expression or activity change during the early postnatal 
period? Is integrin signaling reduced at the onset of the transition from 
proliferative to hypertrophic cardiomyocyte growth? Future studies are needed 
to address these questions. 
Conclusion 
Understanding normal and abnormal cardiac development promises to have 
an impact on the diagnosis and treatment of human and animal heart diseases. 
My studies of cardiac hypertrophy in the dark-like mutant mouse provide new 
insight into the developmental development and transition pathway from 
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proliferative to hypertrophic cardiomyocyte growth. While my genetic studies of 
arrhythmias in German shepherd dogs did not reveal any chromosomal 
regions that were strongly linked to susceptibility to ventricular arrhythmias in 
young dogs, I did demonstrate a significant reduction in ATP2A2/SERCA2 
levels in the hearts of affected dogs. To the best of my knowledge, my studies 
are the first to demonstrate a relationship between the expression 
ATP2A2/SERCA2 and the severity of ventricular arrhythmias. This implicates 
abnormal calcium handling as a key determinant of the severity of inherited 
ventricular arrhythmias and suggests that future genetic studies of these 
animals should pay close attention to genes upstream of ATP2A2 transcription 
as likely candidates. 
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